Crystal form of heterocyclic compound, salt thereof, crystal form of salt thereof and application

By developing the crystal form and salt form of 15-PGDH heterocyclic compound, combining acid and solvent, the problems of insufficient biological activity and poor drug properties of existing compounds in drug preparation are solved, and a more stable drug form and better Application prospects.

CN118908977APending Publication Date: 2024-11-08WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO +1
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410557122.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-23
Filing Date
2024-05-07
Publication Date
2024-11-08

Smart Images

  • Figure CN118908977A_ABST
    Figure CN118908977A_ABST
Patent Text Reader

Abstract

The invention discloses a crystal form of a heterocyclic compound, a salt of the heterocyclic compound, a crystal form of the salt of the heterocyclic compound and application. The invention discloses a pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof. The heterocyclic compound is a compound as shown in a formula I-3A and / or a compound as shown in a formula I-3B. The crystal form of the heterocyclic compound, the salt of the heterocyclic compound and the crystal form of the salt of the heterocyclic compound can be used for medicine preparation and have wide application prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of Chinese patent application No. 2023105131520 filed on May 8, 2023. This application claims the priority of Chinese patent application No. 2024104968301 filed on April 23, 2024. This application cites the full text of the above Chinese patent application. Technical Field

[0002] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a crystal form of a heterocyclic compound, a salt thereof, a crystal form of the salt thereof and an application thereof. Background Art

[0003] The 15-hydroxyprostaglandin dehydrogenase (15-PGDH) gene is located on chromosome 4 at 4q34-q35, with a span of approximately 31kb, a total of 7 exons, and a molecular weight of 29kD. 15-PGDH is composed of 266 amino acids and belongs to the short-chain dehydrogenase (SDR) family. It is a dimer composed of two identical subunits, but some people believe that it is only enzymatically active when it exists as a monomer. 15-PGDH is a key enzyme for the degradation and inactivation of prostaglandins (PGs) and related bioactive eicosane substances. It is widely present in normal tissues of humans and mammals, such as the lungs, kidneys, gastrointestinal tract, thyroid, prostate, and placenta. On the one hand, it can catalyze the oxidation of active 15-hydroxyprostaglandins into 15-ketoprostaglandins with greatly weakened activity, and on the other hand, it can catalyze the oxidation of active 15-hydroxyprostaglandins into 15-ketoprostaglandins with greatly weakened activity in NAD + In the presence of coenzyme factors, it degrades some other non-prostaglandin polycyclic aromatic hydrocarbons and reduces carcinogens and pro-carcinogens produced under physiological or pathological conditions through oxidation reactions.

[0004] The Chinese invention patent application with application number 202211449273.5 describes heterocyclic compounds with 15-PGDH inhibitory activity:

[0005]

[0006] The chemical name of the heterocyclic compound is 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (numbered I-3), and the structure contains the following two isomers:

[0007]

[0008] On the basis of the good biological activity of the compound, it is necessary to develop a suitable salt form and a solid form thereof to obtain improved drugability or other properties. Summary of the invention

[0009] The present invention provides a crystal form of a heterocyclic compound, a salt thereof, a crystal form of the salt thereof and an application thereof. The salt of the heterocyclic compound provided by the present invention, the solid form of the heterocyclic compound or its salt can be used for drug preparation and has good application prospects.

[0010] The present invention provides a pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound).

[0011] The heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B;

[0012]

[0013] Wherein, the pharmaceutically acceptable salt is a salt formed by a heterocyclic compound and an acid; the acid is selected from hydrochloric acid, phosphoric acid, fumaric acid, tartaric acid, malic acid, ethanedisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or oxalic acid.

[0014] In a certain embodiment, in the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the solvent is selected from one or two of isopropyl acetate, acetone, isopropyl alcohol and n-heptane.

[0015] In one embodiment, the heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B:

[0016]

[0017] In one embodiment, when the heterocyclic compound is a compound represented by formula I-3A or a compound represented by formula I-3B, it is a compound represented by formula I-3:

[0018]

[0019] In one embodiment, the heterocyclic compound is a compound represented by formula I-3B

[0020] In one embodiment, in the pharmaceutically acceptable salt of the heterocyclic compound or a solvate thereof, the molar ratio of the heterocyclic compound to the acid is 1:(0.5-2), for example 1:(0.5-1), for example 1:1, 1:0.9 or 1:0.5.

[0021] In one embodiment, in the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the molar ratio of the heterocyclic compound to the solvent is 1:(0.001-2), for example 1:(0.001-1), such as 1:0.05, 1:0.9, 1:0.01, 1:0.04, 1:0.008, 1:0.03, 1:0.3 or 1:0.5.

[0022] In one embodiment, the pharmaceutically acceptable salt or solvate of the heterocyclic compound is:

[0023] A hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of hydrochloric acid, the compound represented by formula I-3B and acetone is 0.9:1:0.9;

[0024] Or, a phosphate of the compound of formula I-3B, wherein the molar ratio of phosphoric acid to the compound of formula I-3B is 1:1;

[0025] Or, a phosphate acetone solvate of the compound of formula I-3B, wherein the molar ratio of phosphoric acid, the compound of formula I-3B and acetone is 1:1:0.05;

[0026] Or, a fumarate salt of the compound of formula I-3B, wherein the molar ratio of fumaric acid to the compound of formula I-3B is 1:1;

[0027] Or, L-tartrate of the compound of formula I-3B, wherein the molar ratio of tartaric acid to the compound of formula I-3B is 1:1;

[0028] Or, L-malate of the compound of formula I-3B, wherein the molar ratio of malic acid to the compound of formula I-3B is 1:1;

[0029] Or, an isopropanol solvate of an edisulphonate of the compound of formula I-3B, wherein the molar ratio of edisulphonic acid, the compound of formula I-3B and isopropanol is 0.5:1:0.5;

[0030] Or, ethanedisulfonate of the compound represented by formula I-3B, wherein the molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 0.5:1;

[0031] Or, an edisulphonate of the compound represented by formula I-3B, wherein the molar ratio of edisulphonic acid to the compound represented by formula I-3B is 1:1;

[0032] Or, ethanedisulfonic acid salt of the compound represented by formula I-3B and acetone n-heptane solvate, wherein the molar ratio of ethanedisulfonic acid, the compound represented by formula I-3B, acetone and n-heptane is 1:1:0.3:0.03;

[0033] Or, p-toluenesulfonate of the compound represented by formula I-3B, wherein the molar ratio of p-toluenesulfonate to the compound represented by formula I-3B is 1:1;

[0034] Or, a methanesulfonate salt of the compound of formula I-3B, wherein the molar ratio of methanesulfonic acid to the compound of formula I-3B is 1:1;

[0035] Or, a methanesulfonate n-heptane solvate of the compound represented by formula I-3B, wherein the molar ratio of methanesulfonic acid, the compound represented by formula I-3B and n-heptane is 1:1:0.008;

[0036] Or, a benzenesulfonate salt of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1:1;

[0037] Or, a benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid, the compound represented by formula I-3B and isopropanol is 1:1:0.01;

[0038] Or, an oxalate of the compound represented by formula I-3B, wherein the molar ratio of oxalic acid to the compound represented by formula I-3B is 1:1.

[0039] In a certain embodiment, the solvate of the pharmaceutically acceptable salt of the heterocyclic compound is not the monohydrochloride monohydrate of the heterocyclic compound.

[0040] The present invention provides a crystalline form A of a compound represented by formula I-3B, which has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 18.6±0.2°, and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation;

[0041] The structure of the compound shown in formula I-3B is:

[0042] In one embodiment, the crystalline form A of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 23.1±0.2°, 17.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°.

[0043] In one embodiment, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 18.6±0.2° and 11.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0044] In one embodiment, the crystalline form A of the compound represented by the formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 23.1±0.2°, 18.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°.

[0045] In one embodiment, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks as shown in Table 1 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0046] In one embodiment, the crystal form A of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Figure 1 shown.

[0047] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the compound represented by formula I-3B has a starting point of an endothermic peak at 160.9±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form A of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 168.4±3°C.

[0048] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the compound represented by formula I-3B is substantially as follows: Figure 2 shown.

[0049] In one embodiment, the thermogravimetric analysis (TGA) curve of Form A of the compound represented by Formula I-3B shows a weight loss of approximately 0.67% in the temperature range of 14.8±3°C to 120°C±3°C.

[0050] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form A of the compound represented by formula I-3B is substantially as follows: Figure 2 shown.

[0051] In one embodiment, the crystalline form A of the compound represented by formula I-3B is a crystalline form of isopropyl acetate solvate of the compound represented by formula I-3B, and the molar ratio of the compound represented by formula I-3B to the isopropyl acetate is 1:0.04.

[0052] The present invention provides a crystalline form B of a compound represented by formula I-3B, which has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2° and 14.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0053] In one embodiment, the crystalline form B of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2°.

[0054] In one embodiment, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0055] In one embodiment, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0056] In one embodiment, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks as shown in Table 2 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0057] In one embodiment, the crystal form B of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Figure 4 shown.

[0058] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the compound represented by formula I-3B has a starting point of an endothermic peak at 164.2±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 171.7±3°C.

[0059] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the compound represented by formula I-3B is substantially as follows: Figure 5 shown.

[0060] In one embodiment, the thermogravimetric analysis (TGA) curve of Form B of the compound represented by Formula I-3B shows a weight loss of approximately 1.61% in the temperature range of 26.6±3°C to 120°C±3°C.

[0061] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form B of the compound represented by formula I-3B is substantially as follows: Figure 5shown.

[0062] The present invention provides a crystalline form of a hydrochloride of a compound represented by formula I-3B, which has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2° and 11.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0063] In one embodiment, in the crystalline form of the hydrochloride salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to hydrochloric acid is 1:0.9.

[0064] In one embodiment, the crystalline form of the hydrochloride of the compound represented by formula I-3B is a crystalline form of the hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, hydrochloric acid and acetone is 1:0.9:0.9.

[0065] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2°.

[0066] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2° and 20.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0067] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2°, 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0068] In one embodiment, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 3 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0069] In one embodiment, the crystalline form of the hydrochloride of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Figure 7 shown.

[0070] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 122.1±3°C and 199.6±3°C.

[0071] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is substantially as follows: Figure 8 shown.

[0072] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B shows a weight loss of about 13.39% in the temperature range of 17.7±3°C to 100°C±3°C, and a weight loss of about 4.54% in the temperature range of 100±3°C to 150°C±3°C.

[0073] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is substantially as follows: Figure 8 shown.

[0074] The present invention provides a crystal form of a phosphate of a compound represented by formula I-3B, which has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2° and 11.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0075] In one embodiment, in the crystal form of the phosphate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to phosphoric acid is 1:1.0.

[0076] In one embodiment, the crystal form of the phosphate of the compound represented by formula I-3B is a crystal form of the phosphate acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, phosphoric acid and acetone is 1:1.0:0.05.

[0077] In one embodiment, the crystalline form of the phosphate of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2°.

[0078] In one embodiment, the crystalline form of the phosphate of the compound represented by formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0079] In one embodiment, the crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0080] In one embodiment, the crystal form of the phosphate of the compound represented by the formula I-3B has diffraction peaks as shown in Table 4 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0081] In one embodiment, the phosphate crystal of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig. 9 shown.

[0082] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B reaches the peak of the endothermic peak at 158.5±3°C.

[0083] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the phosphate of the compound represented by formula I-3B is substantially as follows: Fig.10 shown.

[0084] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the phosphate of the compound represented by formula I-3B shows a weight loss of about 2.07% in the temperature range of 27.4±3°C to 120°C±3°C.

[0085] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the phosphate of the compound represented by formula I-3B is substantially as follows: Fig.10 shown.

[0086] The present invention provides a crystalline form of a fumaric acid complex of a compound represented by formula I-3B, which has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2° and 22.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0087] In one embodiment, in the crystalline form of the fumaric acid complex of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to fumaric acid is 1:1.

[0088] In one embodiment, the fumaric acid complex of the compound represented by formula I-3B is a fumaric acid eutectic of the compound represented by formula I-3B.

[0089] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles: 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2°.

[0090] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2° and 26.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0091] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0092] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B has diffraction peaks as shown in Table 5 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0093] In one embodiment, the crystal form of the fumaric acid complex of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.11 shown.

[0094] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has a starting point of an endothermic peak at 165.2±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 167.2±3°C.

[0095] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is substantially as follows: Fig.12 shown.

[0096] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B shows a weight loss of about 0.36% in the temperature range of 26.2±3°C to 120°C±3°C.

[0097] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is substantially as follows: Fig.12 shown.

[0098] In one embodiment, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is a single crystal of the fumaric acid complex of the compound represented by formula I-3B, which has the following unit cell parameters: orthorhombic system, space group P2 1 2 1 2 1 ; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.451 mg / m 3 .

[0099] The present invention provides a crystalline form of L-tartrate of a compound represented by formula I-3B, which has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2° and 23.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0100] In one embodiment, in the crystalline form of L-tartrate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-tartaric acid is 1:1.

[0101] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2°.

[0102] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2° and 18.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0103] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2°, 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0104] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 6 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0105] In one embodiment, the crystalline form of the L-tartrate salt of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.13 shown.

[0106] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B has a starting point of an endothermic peak at 162.4±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 165.7±3°C.

[0107] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B is substantially as follows: Fig.14 shown.

[0108] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B shows a weight loss of approximately 0.57% in the temperature range of 25.9±3°C to 120°C±3°C.

[0109] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B is substantially as follows: Fig.14 shown.

[0110] The present invention provides a crystalline form of a p-toluenesulfonate salt of a compound represented by formula I-3B, which has a diffraction peak at 6.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0111] In one embodiment, in the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to p-toluenesulfonic acid is 1:1.

[0112] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B uses Cu-Kα radiation and the X-ray powder diffraction pattern expressed in 2θ angles also has diffraction peaks at one or more of the following locations: 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2°.

[0113] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2° and 20.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0114] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0115] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 7 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0116] In one embodiment, the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.15 shown.

[0117] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B reaches the peak of the endothermic peak at 278.9±3°C.

[0118] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is as follows: Fig.16 shown.

[0119] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of approximately 0.89% in the temperature range of 25.9±3°C to 150°C±3°C.

[0120] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is as follows: Fig.16 shown.

[0121] The present invention provides a crystalline form of L-malate of a compound represented by formula I-3B, which has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2° and 22.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0122] In one embodiment, in the crystalline form of L-malate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-malic acid is 1:1.

[0123] In one embodiment, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2°.

[0124] In one embodiment, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2° and 17.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0125] In one embodiment, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0126] In one embodiment, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 8 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0127] In one embodiment, the crystalline form of the L-malate salt of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.17 shown.

[0128] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B has a starting point of an endothermic peak at 120.4±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B reaches peak values ​​of endothermic peaks at 128.1±3°C and 213.6±3°C.

[0129] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B is substantially as follows: Fig.18 shown.

[0130] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the L-malate salt of the compound represented by formula I-3B shows a weight loss of approximately 1.31% in the temperature range of 27.5±3°C to 100°C±3°C.

[0131] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the L-malate salt of the compound represented by formula I-3B is substantially as follows: Fig.18 shown.

[0132] The present invention provides a crystalline form A of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 5.3±0.2° and 18.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0133] In one embodiment, in the crystalline form A of the ethanedisulfonate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:0.5.

[0134] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B is a crystalline form of the edisylate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid and isopropanol is 1:0.5:0.5.

[0135] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B uses Cu-Kα radiation and the X-ray powder diffraction pattern expressed in 2θ angles also has diffraction peaks at one or more of the following locations: 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2°.

[0136] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0137] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0138] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 9 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0139] In one embodiment, the crystalline form A of the edisylate salt of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.19 shown.

[0140] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peak at 162.8±3°C and 239.7±3°C, and reaches the peak value of the exothermic peak at 198.8±3°C.

[0141] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig. 20 shown.

[0142] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 9.08% in the temperature range of 25.2±3°C to 170°C±3°C.

[0143] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig. 20 shown.

[0144] The present invention provides a crystalline form B of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 18.6±0.2°, 19.4±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0145] In one embodiment, in the crystalline form B of the ethanedisulfonate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:0.5.

[0146] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation and the X-ray powder diffraction pattern expressed in 2θ angles also has diffraction peaks at one or more of the following locations: 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2°.

[0147] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2° and 15.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0148] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0149] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 10 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0150] In one embodiment, the crystalline form B of the edisylate salt of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.21 shown.

[0151] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B has a starting point of an endothermic peak at 235.8±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 242.4±3°C.

[0152] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig. 22 shown.

[0153] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 1.84% in the temperature range of 28.4±3°C to 150°C±3°C.

[0154] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form B of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig. 22 shown.

[0155] The present invention provides a crystalline form C of an edisylate salt of a compound represented by formula I-3B, which has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0156] In one embodiment, in the crystalline form C of the ethanedisulfonate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:1.

[0157] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B is a crystalline form of the edisylate salt of the compound represented by formula I-3B acetone n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid, acetone and n-heptane is 1:1:03:0.03.

[0158] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 7.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2°.

[0159] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2° and 17.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0160] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2°, 17.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0161] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 11 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0162] In one embodiment, the crystalline form C of the edisylate salt of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.23 shown.

[0163] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 109.5±3°C and 243.6±3°C.

[0164] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig.24 shown.

[0165] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 7.28% in the temperature range of 28.6±3°C to 150°C±3°C.

[0166] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form C of the edisylate salt of the compound represented by formula I-3B is substantially as follows: Fig.24 shown.

[0167] The present invention provides a crystalline form of a mesylate salt of a compound represented by formula I-3B, which has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2° and 21.8±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0168] In one embodiment, in the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to methanesulfonic acid is 1:1.

[0169] In one embodiment, the crystalline form of the methanesulfonate of the compound represented by formula I-3B is a crystalline form of the methanesulfonate of the compound represented by formula I-3B and n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, methanesulfonic acid and n-heptane is 1:1:0.008.

[0170] In one embodiment, the crystalline form of the mesylate salt of the compound represented by formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2°.

[0171] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2° and 15.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0172] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0173] In one embodiment, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 12 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0174] In one embodiment, the crystalline form of the mesylate salt of the compound represented by formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.25 shown.

[0175] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the mesylate salt of the compound represented by formula I-3B has a starting point of an endothermic peak at 116.3±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form of the mesylate salt of the compound represented by formula I-3B reaches a peak value of the endothermic peak at 124.3±3°C.

[0176] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the mesylate salt of the compound represented by formula I-3B is substantially as follows: Fig.26 shown.

[0177] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B shows a weight loss of approximately 4.53% in the temperature range of 28.4±3°C to 80°C±3°C.

[0178] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the mesylate salt of the compound represented by formula I-3B is substantially as follows: Fig.26 shown.

[0179] The present invention provides a crystalline form of a benzenesulfonate salt of a compound represented by formula I-3B, which has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2° and 21.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0180] In one embodiment, in the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to benzenesulfonic acid is 1:1.

[0181] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is a crystalline form of the benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, benzenesulfonic acid and isopropanol is 1:1:0.01.

[0182] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2°.

[0183] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, and 19.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0184] In one embodiment, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0185] In one embodiment, the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 13 in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0186] In one embodiment, the benzenesulfonate salt of the compound represented by formula I-3B is radiated with Cu-Kα, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig. 27 shown.

[0187] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B reaches the peak of the endothermic peak at 254.1±3°C.

[0188] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is substantially as follows: Fig.28 shown.

[0189] In one embodiment, the thermogravimetric analysis curve (TGA) of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B shows a weight loss of about 1.32% in the temperature range of 28.4±3°C to 150°C±3°C.

[0190] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is substantially as follows: Fig.28 shown.

[0191] The present invention provides a crystalline form of an oxalate of a compound represented by formula I-3B, which has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2° and 16.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0192] In one embodiment, in the crystal form of the oxalate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to oxalic acid is 1:1.

[0193] In one embodiment, the crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation: 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2°.

[0194] In one embodiment, the crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2° and 15.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0195] In one embodiment, the crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2°, 15.4±0.2°, 23.6±0.2°, 22.4±0.2° and 28.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

[0196] In one embodiment, the crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks as shown in Table 14 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles.

[0197] In one embodiment, the crystalline form of the oxalate of the compound represented by formula I-3B is subjected to Cu-Kα radiation, and its X-ray powder diffraction (XRPD) pattern is substantially as follows: Fig.29 shown.

[0198] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 129.7±3°C and 198.2±3°C.

[0199] In one embodiment, the differential scanning calorimetry (DSC) curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B is substantially as follows: Fig.30 shown.

[0200] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B shows a weight loss of approximately 2.27% in the temperature range of 28.4±3°C to 100°C±3°C.

[0201] In one embodiment, the thermogravimetric analysis (TGA) curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B is substantially as follows: Fig.30 shown.

[0202] The present invention provides a method for preparing a crystalline form of the compound represented by the above formula I-3B, which comprises the following steps:

[0203] Crystallizing the mixture of the compound represented by Formula I-3B and the solution to obtain a crystalline form of the compound represented by Formula I-3B or a solvate thereof;

[0204] Wherein, when the crystalline form A of the compound represented by formula I-3B is obtained, the solvent is isopropyl acetate;

[0205] When the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is one or more of methanol, water, acetonitrile and methyl tert-butyl ether.

[0206] In one embodiment, in the method for preparing the crystalline form of the compound shown in Formula I-3B, when the crystalline form A of the compound shown in Formula I-3B is obtained, the crystallization is to cool the mixture of isopropyl acetate and the compound shown in Formula I-3B to room temperature, and dry (for example, volatilize) to obtain the crystalline form A of the compound shown in Formula I-3B.

[0207] In one embodiment, in the method for preparing the crystalline form of the compound represented by formula I-3B, when obtaining the crystalline form B of the compound represented by formula I-3B, the solvent is a mixed solution of methanol and water or a mixed solution of acetonitrile and methyl tert-butyl ether, preferably a mixed solution of methanol and water with a volume ratio of methanol to water of 1:5.

[0208] In a certain embodiment, in the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the crystallization is to crystallize a mixture of the compound represented by formula I-3B and methanol and water (for example, a mixed solution of methanol and water in a volume ratio of 1:5) at 50°C (for example, stirring at 50°C for 3 days), and drying (for example, drying at room temperature) to obtain the crystalline form B of the compound represented by formula I-3B.

[0209] The present invention provides a method for preparing the above-mentioned crystal form, which comprises the following steps:

[0210] Crystallizing a mixture of the compound represented by formula I-3B, an acid and a solvent;

[0211] Wherein, when the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is obtained, the acid is hydrochloric acid and the solvent is acetone;

[0212] When the crystalline form of the phosphate of the compound represented by formula I-3B is obtained, the acid is phosphoric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0213] When the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is obtained, the acid is fumaric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0214] When the crystalline form of L-tartrate of the compound represented by formula I-3B is obtained, the acid is tartaric acid, and the solvent is a mixed solution of acetone and n-heptane;

[0215] When the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is obtained, the acid is p-toluenesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0216] When the crystal form of L-malate of the compound represented by formula I-3B is obtained, the acid is malic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0217] When the crystalline form A of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropanol;

[0218] When the crystalline form B of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropyl acetate;

[0219] When the crystalline form C of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0220] When the crystalline form of the mesylate salt of the compound represented by formula I-3B is obtained, the acid is methanesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane;

[0221] When the crystalline form of benzenesulfonate of the compound represented by formula I-3B is obtained, the acid is benzenesulfonic acid and the solvent is isopropanol;

[0222] When the crystalline form of the oxalate of the compound represented by formula I-3B is obtained, the acid is oxalic acid, and the solvent is a mixed solution of acetone and n-heptane.

[0223] In one embodiment, in the preparation method, when the solvent is a mixed solution of acetone and n-heptane, the volume ratio of acetone to n-heptane is 1:1.

[0224] In one embodiment, in the preparation method, the molar ratio of the compound represented by formula I-3B to the acid is conventional in the art, for example, the molar ratio of the heterocyclic compound to the acid is 1:1.

[0225] In one embodiment, the preparation method comprises the following steps: suspending (e.g., suspending and stirring) the compound represented by formula I-3B, an acid and a solvent to obtain a mixture, and crystallizing to obtain a crystalline form.

[0226] In a certain embodiment, in the preparation method, when the obtained crystal form is the hydrochloride of the compound shown in formula I-3B, the L-malate of the compound shown in formula I-3B, the crystalline form B of the edisylate of the compound shown in formula I-3B, the crystalline form C of the edisylate of the compound shown in formula I-3B, the crystalline form of the methanesulfonate of the compound shown in formula I-3B or the crystalline form of the benzenesulfonate of the compound shown in formula I-3B, the crystallization comprises the following steps: subjecting the mixture of the compound shown in formula I-3B, acid and solvent to temperature cycling (for example, in the range of 50°C-5°C, with a heating rate of 4.5°C / min and a cooling rate of 0.1°C / min, and heating and cooling cycles at a constant temperature of 50°C or 5°C for 2 hours), and drying (for example, vacuum drying at room temperature).

[0227] In a certain embodiment, in the preparation method, when the obtained crystal form is the phosphate of the compound shown in formula I-3B, the fumaric acid complex of the compound shown in formula I-3B, the L-tartrate of the compound shown in formula I-3B, the p-toluenesulfonate of the compound shown in formula I-3B, the ethanedisulfonate of the compound shown in formula I-3B, or the oxalate of the compound shown in formula I-3B, the crystallization comprises the following steps: drying the mixture of the compound shown in formula I-3B, acid and solvent (for example, vacuum drying at room temperature).

[0228] The present invention provides a pharmaceutical composition, which comprises a pharmaceutically acceptable salt of the above heterocyclic compound or a solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of the heterocyclic compound), and a pharmaceutically acceptable carrier.

[0229] The present invention provides a pharmaceutical composition, which comprises a substance X and a pharmaceutically acceptable carrier, wherein the substance X is the crystal form A of the compound shown in the above formula I-3B, the crystal form B of the compound shown in the formula I-3B, the crystal form of the hydrochloride of the compound shown in the formula I-3B, the crystal form of the phosphate of the compound shown in the formula I-3B, the crystal form of the fumaric acid complex of the compound shown in the formula I-3B, the crystal form of the L-tartrate of the compound shown in the formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in the formula I-3B, the crystal form of the L-malate of the compound shown in the formula I-3B, the crystal form A of the edisylate of the compound shown in the formula I-3B, the crystal form B of the edisylate of the compound shown in the formula I-3B, the crystal form C of the edisylate of the compound shown in the formula I-3B, the crystal form of the methanesulfonate of the compound shown in the formula I-3B, the crystal form of the benzenesulfonate of the compound shown in the formula I-3B, or the crystal form of the oxalate of the compound shown in the formula I-3B.

[0230] In the pharmaceutical composition, the crystal form of the fumaric acid complex of the compound represented by formula I-3B may be a single crystal of the fumaric acid complex of the compound represented by formula I-3B.

[0231] The present invention provides a pharmaceutically acceptable salt of the above heterocyclic compound or a solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound), the above pharmaceutical composition or the use of substance X;

[0232] The substance X is the crystal form A of the compound shown in the above formula I-3B, the crystal form B of the compound shown in the formula I-3B, the crystal form of the hydrochloride of the compound shown in the formula I-3B, the crystal form of the phosphate of the compound shown in the formula I-3B, the crystal form of the fumaric acid complex of the compound shown in the formula I-3B, the crystal form of the L-tartrate of the compound shown in the formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in the formula I-3B, the crystal form of the L-malate of the compound shown in the formula I-3B, the crystal form A of the edisylate of the compound shown in the formula I-3B, the crystal form B of the edisylate of the compound shown in the formula I-3B, the crystal form C of the edisylate of the compound shown in the formula I-3B, the crystal form of the methanesulfonate of the compound shown in the formula I-3B, the crystal form of the benzenesulfonate of the compound shown in the formula I-3B, or the crystal form of the oxalate of the compound shown in the formula I-3B;

[0233] The applications include: inhibiting 15-PGDH; and / or preventing and / or treating diseases related to 15-PGDH; and / or preparing 15-PGDH inhibitors, and / or preparing drugs, pharmaceutical compositions or preparations for preventing and / or treating diseases related to 15-PGDH.

[0234] Preferably, the 15-PGDH-related diseases include, but are not limited to, one, two or more of: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease and kidney disease.

[0235] Preferably, the 15-PGDH-related diseases include, but are not limited to, one, two or more of: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, ear diseases, eye diseases, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease and kidney disease. Preferably, the 15-PGDH-related diseases include, but are not limited to: fibrotic diseases (such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, etc., liver fibrosis, renal fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases [such as chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, asthma and exacerbation of lung disease, inflammatory bowel disease (IBD) (such as ulcerative colitis and Crohn's disease), peptic ulcer (such as NSAID-induced ulcer), autoinflammatory diseases (such as Behcet's disease), vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome (such as chronic prostatitis / chronic pelvic pain syndrome)], cardiovascular diseases (such as pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke and peripheral circulatory disorders), renal disease (such as chronic kidney disease and renal failure), trauma (such as diabetic ulcer, burns, etc.), and prostatitis syndrome. Injury, pressure ulcer, acute mucosal injury, including Stevens-Johnson syndrome, mucosal injury (such as mucositis or stomatitis), injury associated with anticancer chemotherapeutic agents (anticancer chemotherapeutic agents are mainly such as alkylating agents, DNA synthesis inhibitors, DNA gyrase inhibitors) or antimetabolites, cellular or humoral immunotherapy or radiation-related injury), autoimmune diseases (such as multiple sclerosis or rheumatoid arthritis), graft-versus-host disease (GVHD), hair growth, osteoporosis, ear diseases (such as hearing loss, tinnitus, vertigo and balance disorders), eye diseases (such as glaucoma and dry eyes), neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and neural cell death (such as psychoneurological diseases, neuropathy, neurotoxic diseases, neuropathic pain and neurodegenerative diseases), liver regeneration, muscle regeneration (such as muscle atrophy, muscular dystrophy and muscle injury) and cervical disease.

[0236] Preferably, the tissue damage is liver damage and / or muscle damage (such as muscle atrophy and muscular dystrophy).

[0237] Preferably, the 15-PGDH-related diseases include but are not limited to idiopathic pulmonary fibrosis (IPF).

[0238] Preferably, the prevention and / or treatment of 15-PGDH-related diseases includes but is not limited to: liver regeneration.

[0239] Preferably, the 15-PGDH-related diseases include but are not limited to: liver damage.

[0240] Preferably, the 15-PGDH-related diseases include but are not limited to inflammatory bowel disease (IBD).

[0241] The present invention provides a pharmaceutically acceptable salt or solvate thereof (referring to a solvate of a pharmaceutically acceptable salt of a heterocyclic compound), the pharmaceutical composition or the use of substance X, wherein the use is for preventing and / or treating the following diseases, and / or the use is for preparing a medicament for preventing or treating the following diseases; the diseases are one or more of fibrotic diseases, inflammatory diseases or tissue damage;

[0242] The substance X is the crystal form A of the compound shown in the above formula I-3B, the crystal form B of the compound shown in the formula I-3B, the crystal form of the hydrochloride of the compound shown in the formula I-3B, the crystal form of the phosphate of the compound shown in the formula I-3B, the crystal form of the fumaric acid complex of the compound shown in the formula I-3B, the crystal form of the L-tartrate of the compound shown in the formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in the formula I-3B, the crystal form of the L-malate of the compound shown in the formula I-3B, the crystal form A of the edisylate of the compound shown in the formula I-3B, the crystal form B of the edisylate of the compound shown in the formula I-3B, the crystal form C of the edisylate of the compound shown in the formula I-3B, the crystal form of the methanesulfonate of the compound shown in the formula I-3B, the crystal form of the benzenesulfonate of the compound shown in the formula I-3B, or the crystal form of the oxalate of the compound shown in the formula I-3B;

[0243] The fibrotic disease, the inflammatory disease and the tissue damage may all be the same as described above.

[0244] In the application, the crystal form of the fumaric acid complex of the compound represented by formula I-3B may be a single crystal of the fumaric acid complex of the compound represented by formula I-3B.

[0245] Terminology explanation:

[0246] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in the examples, etc., can be arbitrarily combined and combined with each other. The definitions and compound structures after such combinations and combinations shall fall within the scope of the description of this application. Unless otherwise specified, the terms used in this invention have the following meanings:

[0247] The term "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant governmental regulatory authorities as acceptable for human or livestock use.

[0248] The term "treat" refers to therapeutic treatment. When referring to a specific condition, treatment means: (1) ameliorating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade leading to or causing the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.

[0249] The term "prevent" refers to the reduction of the risk of acquiring or developing a disease or disorder.

[0250] The term "inflammatory bowel disease," or IBD, is used to describe diseases that involve chronic inflammation of the digestive tract. The main types include: ulcerative colitis and Crohn's disease. Ulcerative colitis causes inflammation and ulcers in the superficial lining of the large intestine (colon) and rectum. Crohn's disease is characterized by inflammation of the lining of the digestive tract, which often affects deeper layers of the digestive tract.

[0251] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0252] The reagents and raw materials used in the present invention are commercially available.

[0253] The positive and progressive effects of the present invention are that the crystal forms of heterocyclic compounds, pharmaceutically acceptable salts of heterocyclic compounds or solvates thereof provided by the present invention have good effects and are easy to prepare into medicines. BRIEF DESCRIPTION OF THE DRAWINGS

[0254] Figure 1 The X-ray powder diffraction pattern of Form A of the compound represented by Formula I-3B.

[0255] Figure 2 The differential scanning calorimetry curve and thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B are shown.

[0256] Figure 3 This is the XRPD pattern of the temperature-variable test of Form A of the compound represented by Formula I-3B.

[0257] Figure 4 The X-ray powder diffraction pattern of Form B of the compound represented by Formula I-3B.

[0258] Figure 5 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form B of the compound represented by formula I-3B are shown.

[0259] Figure 6 This is the XRPD pattern of the temperature-variable test of Form B of the compound represented by Formula I-3B.

[0260] Figure 7 The X-ray powder diffraction pattern of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B.

[0261] Figure 8 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B are shown.

[0262] Fig. 9 The X-ray powder diffraction pattern is the crystal form of the phosphate of the compound represented by formula I-3B.

[0263] Fig.10 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystal form of the phosphate of the compound represented by formula I-3B.

[0264] Fig.11 This is the X-ray powder diffraction pattern of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B.

[0265] Fig.12 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B.

[0266] Fig.13 The X-ray powder diffraction pattern of the crystalline form of L-tartrate of the compound represented by formula I-3B.

[0267] Fig.14 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of L-tartrate of the compound represented by formula I-3B.

[0268] Fig.15 The X-ray powder diffraction pattern of the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B.

[0269] Fig.16 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B are shown.

[0270] Fig.17 The X-ray powder diffraction pattern of the crystalline form of L-malate of the compound represented by formula I-3B.

[0271] Fig.18 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of L-malate of the compound represented by formula I-3B.

[0272] Fig.19 The X-ray powder diffraction pattern of the crystalline form A of the edisylate salt of the compound represented by formula I-3B.

[0273] Fig. 20 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B are shown.

[0274] Fig.21 The X-ray powder diffraction pattern of the crystalline form B of the edisylate salt of the compound represented by formula I-3B.

[0275] Fig. 22 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B.

[0276] Fig.23 The X-ray powder diffraction pattern of the crystalline form C of the edisylate salt of the compound represented by formula I-3B.

[0277] Fig.24 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B are shown.

[0278] Fig.25 The X-ray powder diffraction pattern of the crystalline form of the mesylate salt of the compound represented by formula I-3B.

[0279] Fig.26 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the mesylate salt of the compound represented by formula I-3B are shown.

[0280] Fig. 27 The X-ray powder diffraction pattern of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B.

[0281] Fig.28 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B are shown.

[0282] Fig.29 The X-ray powder diffraction pattern of the crystalline form of the oxalate salt of the compound represented by formula I-3B.

[0283] Fig.30 The differential scanning calorimetry curve and thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B are shown.

[0284] Fig.31 This is the single crystal structure diagram of compound R1.

[0285] Fig.32 The compound represented by formula I-3B is in H 2 XRPD pattern of dynamic solubility in O.

[0286] Fig.33 The XRPD diagram of the dynamic solubility of the compound represented by formula I-3B in SGF.

[0287] Fig.34 This is the XRPD diagram of the dynamic solubility of the compound represented by formula I-3B in FaSSIF.

[0288] Fig.35 This is the XRPD diagram of the dynamic solubility of the compound represented by formula I-3B in FeSSIF.

[0289] Fig.36 The crystalline form of the fumaric acid complex of the compound shown in formula I-3B is 2 XRPD pattern of dynamic solubility in O.

[0290] Fig.37 This is the XRPD diagram of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in SGF.

[0291] Fig.38 This is the XRPD diagram of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in FaSSIF.

[0292] Fig.39 This is the XRPD diagram of the dynamic solubility of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B in FeSSIF.

[0293] Fig.40 This is the XRPD pattern for stability evaluation of Form A of the compound represented by Formula I-3B.

[0294] Fig.41 This is the XRPD pattern for stability evaluation of Form B of the compound represented by Formula I-3B.

[0295] Fig.42 This is an XRPD pattern for evaluating the crystalline stability of the fumaric acid complex of the compound represented by Formula I-3B.

[0296] Fig.43 This is an XRPD pattern for evaluating the crystalline stability of the L-tartrate salt of the compound represented by Formula I-3B.

[0297] Fig.44 XRPD diagram of Form A of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0298] Fig.45 XRPD diagram of Form B of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0299] Fig.46 The XRPD diagram of the crystal form of the fumaric acid complex of the compound represented by Formula I-3B before and after the hygroscopicity test.

[0300] Fig.47 The XRPD diagram of the crystal form of L-tartrate of the compound shown in Formula I-3B before and after the hygroscopicity test.

[0301] Fig.48 This is a comparison chart of the XRPD pattern of the fumaric acid complex crystal fitting of the compound shown in I-3B and the measured XRPD pattern.

[0302] Fig.49 This is an ellipsoid diagram of the molecular structure of the fumaric acid complex crystal of the compound shown in I-3B. DETAILED DESCRIPTION

[0303] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0304] Symbol or unit:

[0305] IC 50 : Half inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved

[0306] M: mol / L, for example, n-butyllithium (14.56 mL, 29.1 mmol, 2.5 M n-hexane solution) means a n-butyllithium n-hexane solution with a molar concentration of 2.5 mol / L

[0307] N: equivalent concentration, for example, 2N hydrochloric acid means 2 mol / L hydrochloric acid solution

[0308] Reagents:

[0309] Comparison table of Chinese and English names of solvents selected in the examples

[0310]

[0311]

[0312] Crystal form detection instruments and methods:

[0313] 1. X-ray powder diffraction (XRPD)

[0314] The XRPD pattern was collected on an X-ray powder diffraction analyzer produced by PANalytacal, and the scanning parameters are shown in the following table:

[0315]

[0316] 2. X-ray single crystal diffraction

[0317] Test environment: test temperature: 200(2)K, room temperature: 24°C, relative humidity: 34%, X-ray single crystal diffraction method is as follows:

[0318]

[0319]

[0320] 3. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC)

[0321] TGA and DSC images were collected on TA5500 thermogravimetric analyzer and TA2500 differential scanning calorimeter respectively. The following table lists the test parameters:

[0322]

[0323] 4. Solution NMR:

[0324] Liquid-state NMR spectra were collected on a Bruker 400M NMR instrument using DMSO-d6 as solvent.

[0325] 5. High Performance Liquid Chromatography (HPLC):

[0326] In the experiment, the purity test, dynamic solubility and stability test were completed by UPLC ultra-high performance liquid chromatography, and the analysis conditions are shown in the following table:

[0327]

[0328]

[0329] 6. Dynamic moisture sorption (DVS):

[0330] Dynamic moisture sorption (DVS) curves were collected on the DVS Intrinsic Plus of SMS (Surface Measurement Systems). The relative humidity at 25°C was corrected using the deliquescent point of LiCl, Mg(NO3)2 and KCl. The DVS test parameters are listed in the table below:

[0331]

[0332] 7. Ion Chromatography (IC):

[0333] The instrument parameters for determining the molar ratio of counter ions by ion chromatography (IC) are listed in the analytical conditions as shown in the following table:

[0334]

[0335] Example 1 Preparation of 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one

[0336] The synthetic route of the target compound is as follows:

[0337]

[0338] Step 1: 4-Bromo-2-hydrazinopyridine (B3-2)

[0339]

[0340] 80% hydrazine hydrate solution (17 mL) was added to a solution of 4-bromo-2-fluoropyridine (5 g, 28.4 mmol) in ethanol (50 mL), and the reaction mixture was stirred at room temperature for 12 h, concentrated, and the residue was diluted with water (50 mL), extracted with ethyl acetate (50 mL*3), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered and dried to give 4-bromo-2-hydrazinopyridine (3.7 g, yield 69.3%).

[0341] LC-MS, M / Z(ESI):187.9[M+H] + .

[0342] Step 2: 7-Bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B3-3)

[0343]

[0344] Dissolve 4-bromo-2-hydrazinopyridine (3.2 g, 17.02 mmol) in tetrahydrofuran (30 mL), add carbonyldiimidazole (5.52 g, 34.0 mmol), stir at room temperature for 12 h, dilute with water (50 mL), extract with ethyl acetate (50 mL*3), combine the organic phases, dry over anhydrous sodium sulfate, filter and spin dry, and slurry with ethyl acetate (10 mL) to obtain 7-bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (2.2 g, yield 60.4%).

[0345] LC-MS, M / Z(ESI):213.9[M+H] + .

[0346] Step 3: 7-Bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B3-4)

[0347]

[0348] At room temperature, iodomethane (995 mg, 7.01 mmol) was added dropwise to a mixture of 7-bromo-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (500 mg, 2.33 mmol) and cesium carbonate (1.14 g, 3.50 mmol) in DMF (5 mL), stirred at room temperature for 3 h, diluted with water (20 mL), extracted with ethyl acetate (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered and dried, and the crude product was separated and purified by silica gel column (petroleum ether: ethyl acetate (V / V) = 5:1-1:1) to give 7-bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (400 mg, yield 75%).

[0349] LC-MS, M / Z(ESI):227.9[M+H] + .

[0350] Step 4: 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one

[0351]

[0352] Under nitrogen protection, (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridin-6-yl)methanone (35.0 mg, 119 μmol), cesium carbonate (155 mg, 477 μmol), 7-bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (40.8 mg, 179 μmol), bis(dibenzylideneacetone)palladium (6.86 mg, 11.9 μmol) and 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (69.0 mg, 119 μmol) were added to dioxane (1 mL), the reaction was stirred at 100°C for 12 h, and the reaction solution was concentrated to obtain a crude product. The crude product was then separated and purified using a silica gel column (petroleum ether: ethyl acetate (V / V) = 5:1-1:1) to obtain the target compound 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridine-3(2H)-one (Compound I-3) (20.0 mg, yield 38.1%).

[0353]

[0354] The products were separated by SFC (chromatographic column: Chiralpak AD-3 50×4.6mm ID, 3μm, mobile phase: mobile phase A: CO 2 , mobile phase B: IPA + ACN (0.05 vol% DEA);

[0355] Isocratic elution: 50 vol% IPA + ACN (0.05 vol% DEA) in CO 2 , flow rate: 3mL / min; detector: PDA, column temperature: 35°C; column pressure: 100Bar). The isomer (compound I-3A (i.e., the compound shown in formula I-3A of the present application)) (RT = 0.743min) and the isomer (compound I-3B (i.e., the compound shown in formula I-3B of the present application), after confirmation, its structure is as follows) (RT = 1.670min).

[0356]

[0357] 1 H NMR(400MHz,DMSO)δ8.04(d,1H),7.81(d,1H),7.61(d,1H),6.68(d,1H),6.58(dd,2.0Hz,1H),3.90(d,1H),3.70 -3.52(m,5H),3.48(s,3H),2.18(dt,1H),2.13-1.93(m,5H),1.06(dd,2H).

[0358] LC-MS, M / Z(ESI):441.1[M+H] + .

[0359] Example 1-1 Preparation of the compound represented by formula I-3B

[0360] The synthetic route of the target compound is as follows:

[0361]

[0362] Step 1: Synthesis of methyl (1aS, 7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3).

[0363]

[0364] To the reaction flask, add (1aS,7bR)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid methyl ester (R1) (159.6 mg, 0.7 mmol), 7-bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (2) (130 mg, 0.6 mmol), Pd 2 (dba) 3 (91.6 mg, 0.1 mmol), ligand L (ligand L is Xantphos) (57.9 mg, 0.1 mmol) and cesium carbonate (488.7 mg, 1.5 mmol). After replacing with nitrogen three times, anhydrous solvent 1,4-dioxane (4 mL) was added and reacted at 85°C for 12 hours. After cooling to room temperature, water was added to quench the reaction, extracted with ethyl acetate, the organic phase was concentrated to dryness and mixed, and separated and purified by silica gel column (dichloromethane: methanol, V / V = 20:1) to obtain methyl (1aS, 7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a, 2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3) (200 mg, yield: 85.7%).

[0365] LC-MS, M / Z(ESI):352.1[M+H] + .

[0366] Ligand L:

[0367] Step 2: Synthesis of (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4).

[0368]

[0369] Methyl (1aS, 7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylate (3) (200 mg, 0.6 mmol) was dissolved in a mixed solution of tetrahydrofuran (4 mL), methanol (0.8 mL) and water (0.8 mL), and then lithium hydroxide monohydrate (100 mg, 2.4 mmol) was added. The mixture was reacted at room temperature for 12 hours. After the reaction was complete, water was added to quench the reaction. 1 M hydrochloric acid was added to adjust the pH to 1. The mixture was extracted with ethyl acetate. The organic phase was concentrated to dryness to obtain (1aS, 7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a, 2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4), which was used directly in the next step.

[0370] LC-MS, M / Z(ESI):338.1[M+H] + .

[0371] Step 3: Synthesis of 7-((1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropyl[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridine-3(2H)-one (5).

[0372]

[0373] Under nitrogen protection, a solution of (1aS,7bR)-3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-1a,2,3,7b-tetrahydro-1H-cyclopropyl[c][1,8]naphthyridine-6-carboxylic acid (4) (120 mg, 0.4 mmol) in ethyl acetate (2 mL) was added. 4,4-difluoropiperidine hydrochloride (72.7 mg, 0.6 mmol) and pyridine were added to the mixture. (0.2 mL), then add T 3 P DMF solution (0.6 8mL, 0.5mmol), react at room temperature for 3 hours. Add water to quench the reaction, extract with ethyl acetate, concentrate the organic phase to dryness and mix the sample, separate and purify with silica gel column (dichloromethane: methanol, V / V = 20:1), and obtain 7-((1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropyl[c][1,8]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridine-3(2H)-one (5) (132mg, yield: 75%)

[0374] LC-MS, M / Z(ESI):441.1[M+H] +

[0375] 1 H NMR (400 MHz, DMSO-d 6 ): δ8.09(d,1H),7.71(d,1H),7.59(d,1H),6.55–6.52(m,2H),3.95(d,1H) ,3.75–3.69(m,5H),3.63(s,3H),2.10–2.03(m,6H),1,22–1.12(m,2H)ppm.

[0376] The product was subjected to SFC (chromatographic column: Chiralpak AD-3 50×4.6mm ID, 3μm, mobile phase: mobile phase A: CO 2 , mobile phase B: IPA + ACN (0.05 vol% DEA);

[0377] Isocratic elution: 50 vol% IPA + ACN (0.05 vol% DEA) in CO 2 , flow rate: 3 mL / min; detector: PDA, column temperature: 35° C.; column pressure: 100 Bar). The retention reagent RT of compound I-3B (i.e., the compound represented by formula I-3B of the present application) is 1.674 min.

[0378] Single crystal preparation method: Weigh 5 mg (1aS, 7bR)-1a, 2, 3, 7b-tetrahydro-1H-cyclopropyl [c] [1, 8] naphthyridine-6-carboxylic acid methyl ester (R1) into a 2 ml liquid chromatography-mass spectrometer, add 0.4 mL ethyl acetate to dissolve it, then add 0.6 mL petroleum ether to mix evenly, and place the liquid chromatography-mass spectrometer at room temperature to obtain colorless transparent crystals after the solvent evaporates naturally (about 2 days). Single crystal structure analysis, compound R1 single crystal structure as shown Fig.31 As shown, its main crystal parameter data are as follows:

[0379]

[0380]

[0382] The free base is difficult to recrystallize and is prone to gelation. The free base of the compound shown in Formula I-3B obtained in Example 1 is dissolved in a toluene and dimethyl ether solvent system without solid precipitation. The solid can be precipitated by stirring for a long time using the THF / MTBE system, but the time required is long, which is not conducive to factory scale-up production. Large pieces of solid are easily produced during the solidification of the gel, and the sample is severely agglomerated, which is easy to get stuck on the stirring paddle and is difficult to stir.

[0383] Example 2 Crystalline Form A of the Compound of Formula I-3B

[0384] The compound of formula I-3B (RT=1.670 min) obtained in Example 1 was slowly cooled in IPAc and then volatilized to room temperature to obtain the crystalline form A of the compound of formula I-3B. The characterization data are as follows:

[0385] The XRPD diffraction peak data of the crystalline form A of the compound represented by formula I-3B are shown in the following table:

[0386]

[0387]

[0389] The characterization data of the crystalline form A of the compound represented by formula I-3B are shown in the following table:

[0390]

[0392] The NMR data of Form A of the compound shown in Formula I-3B are as follows:

[0393]

[0394]

[0395] According to NMR, the molar ratio of the residual solvent IPAc to the compound of formula I-3B is about 0.04:1 (0.9 wt%). It is speculated that the crystalline form A of the compound of formula I-3B is anhydrous crystalline form.

[0396] Variable temperature XRPD heating experiment:

[0397] To investigate the crystalline properties of the crystalline form A of the compound shown in formula I-3B, the crystalline form A of the compound shown in formula I-3B was heated to 100°C to 180°C in a nitrogen flow, and a variable temperature XRPD (VT-XRPD) experiment was performed on the sample. The results are as follows: Figure 3 As shown, compared with 30℃, no nitrogen (30℃, No N 2 ) and nitrogen (30℃, N 2 ) samples, the samples were heated to 100℃ and 150℃ under N2 protection (100℃, N 2 and 150℃, N 2 ), the crystal form did not change, and was heated to 180°C (180°C, N 2 ) and cooled to room temperature (cooled to 30°C, N 2 ), the crystalline form changes to an amorphous form. It is speculated that the crystalline form A of the compound shown in formula I-3B is an anhydrous crystalline form.

[0398] Example 3: Preparation of Form B of the Compound of Formula I-3B

[0399] The compound of formula I-3B (RT = 1.670 min) obtained in Example 1 was suspended and stirred in MeOH / H2O (1:5, v:v) at 50°C for 3 days to obtain Form B of the compound of formula I-3B, which was dried at room temperature overnight and then characterized.

[0400] The XRPD diffraction peak data of the crystalline form B of the compound represented by formula I-3B are shown in the following table:

[0401]

[0402]

[0404] The characterization data of the crystalline form B of the compound represented by formula I-3B are as follows:

[0405]

[0407] The NMR data of Form B of the compound represented by Formula I-3B are as follows:

[0408]

[0409]

[0410] No residual solvent was observed in the NMR data, and Form B was an anhydrous crystalline form.

[0411] Variable temperature XRPD experiment:

[0412] To investigate the crystal properties of the crystal form B of the compound shown in formula I-3B, the crystal form B of the compound shown in formula I-3B was heated to 100°C to 180°C in a nitrogen flow, and a variable temperature XRPD (VT-XRPD) experiment was performed on the sample. The results are shown in FIG. Figure 6 As shown, compared with 30℃, no nitrogen (30℃, No N 2 ) and nitrogen (30℃, N 2 ) samples, the samples were heated to 100℃ and 150℃ under N2 protection (100℃, N 2 and 150℃, N 2 ), the crystal form did not change, and was heated to 180°C (180°C, N 2 ) and cooled to room temperature (cooled to 30°C, N 2 ), the crystalline form changes to an amorphous form. It is speculated that the crystalline form B of the compound shown in formula I-3B is an anhydrous crystalline form.

[0413] Example 4 Preparation of the salt of the compound represented by formula I-3B or its solvate

[0414] 4.1 Crystalline Form of Hydrochloride of the Compound Represented by Formula I-3B

[0415] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of hydrochloric acid (37% hydrochloric acid aqueous solution) in acetone / n-heptane (1:1, v:v) were suspended and stirred at room temperature overnight to form a jelly, and the jelly was subjected to temperature cycle (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain the crystalline form of the hydrochloride of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0416] The XRPD diffraction peak data of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B are shown in the following table:

[0417]

[0418]

[0420] The crystal characterization data of the hydrochloride salt of the compound represented by formula I-3B are as follows:

[0421]

[0423] The NMR data of the crystalline form of the hydrochloride salt of the compound represented by formula I-3B are as follows:

[0424]

[0425]

[0426] According to NMR data, the molar ratio of residual solvent acetone to the compound of formula I-3B is 0.9 (10.3 wt%). HPLC / IC results show that the molar ratio of hydrochloric acid to the compound of formula I-3B is 0.9.

[0427] 4.2 Crystalline Form of Phosphate Salt of Compound Represented by Formula I-3B

[0428] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of phosphoric acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of the phosphate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0429] The XRPD diffraction peak data of the phosphate salt of the compound represented by formula I-3B are shown in the following table:

[0430]

[0431] The crystal characterization data of the phosphate of the compound represented by formula I-3B are as follows:

[0432]

[0433]

[0435] The NMR data of the crystalline form of the phosphate of the compound represented by formula I-3B:

[0436] # ppm integral 1 8.06 (1H,d) 2 7.83 (1H,d) 3 7.64 (1H,d) 4 6.71 (1H,d) 5 6.60 (1H,dd) 6 3.92 (1H,d) 7 3.68-3.58 (5H,m) 8 3.50 (3H,s) 9 2.23-2.17 (1H,m) 10 2.12-1.97 (5H,m) 11 1.10-1.03 (2H,m)

[0437] According to the NMR data, the molar ratio of the residual solvent acetone to the compound of formula I-3B is 0.05 (0.5 wt%). The HPLC / IC results show that the molar ratio of phosphoric acid to the compound of formula I-3B is 1.0.

[0438] 4.3 Crystalline Form of Fumaric Acid Complex of the Compound Represented by Formula I-3B

[0439] Method 1: 300.6 mg of Form A of the compound represented by Formula I-3B and 80.0 mg of an equimolar amount of fumaric acid were weighed into a 5-mL vial, 3 mL of acetone / n-heptane (1:1, v:v) was added, suspended and stirred at room temperature for 3 days, and centrifuged at room temperature to obtain a fumaric acid complex of the compound represented by Formula I-3B.

[0440] The XRPD diffraction peak data of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B are shown in the following table:

[0441]

[0442]

[0444] The crystal characterization data of the fumaric acid complex of the compound represented by formula I-3B are as follows:

[0445]

[0447] The NMR data of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B are as follows:

[0448] # ppm integral 1 8.06 (1H,d) 2 7.83 (1H,d) 3 7.64 (1H,d) 4 6.71 (1H,d) 5 6.63 (2H,s) 6 6.60 (1H,dd) 7 3.92 (1H,d) 8 3.61-3.68 (5H,m) 9 3.51 (3H,s) 10 2.23-2.17 (1H,m) 11 2.12-2.00 (5H,m) 12 1.10-1.06 (2H,m)

[0449] In order to further study the molecular structure of the above crystals, a single crystal of the fumaric acid complex of the compound shown in I-3B was obtained by method 2. Method 2: Weigh the compound shown in formula I-3B (~15 mg) and add it to an EP tube, add acetone (0.75 mL), shake until the sample is dissolved, pass the solution through a microporous filter membrane into a 2 mL transparent glass bottle, add n-heptane (0.75 mL), separate the solution into layers, seal it with a sealing film, poke two small holes, and volatilize it at room temperature for about 2 days to precipitate transparent crystals to obtain a fumaric acid complex (single crystal) of the compound shown in formula I-3B.

[0450] The single crystal of the fumaric acid complex of the compound represented by formula I-3B obtained in method 2 was subjected to X-ray single crystal diffraction, and the crystallographic parameters were measured as follows:

[0451]

[0452]

[0453]

[0454] According to the X-ray single crystal diffraction results, fumaric acid is connected to the compound shown in formula I-3B in the form of hydrogen bonds. The distance between the hydrogen atom and the oxygen atom is 0.84A, and the distance between the hydrogen atom and the nitrogen atom is 1.89A. The hydrogen atom is closer to the oxygen atom, indicating that the single crystal sample forms a cocrystal (i.e., (1aS, 7bR)-7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a, 2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridine-3(2H)-one fumaric acid cocrystal). The molar ratio of fumaric acid to the compound shown in formula I-3B is 1.0, and no residual solvent signal is observed by NMR.

[0455] Crystalline hydrogen bonding of the fumaric acid complex of the compound shown in formula I-3B ( and °) are shown in the following table:

[0456] DH...A d(DH) d(H...A) d(D...A) <(DHA) C(19)-H(19)...N(5) 0.95 2.56 3.155(2) 121.1 O(4)-H(4)...O(1) 0.84 1.79 2.6175(16) 169.1 O(5)-H(5)...N(2) 0.84 1.89 2.6755(16) 155.1

[0457] The molecular structure ellipsoid model of the single crystal of the fumaric acid complex of the compound shown in Formula I-3B is as follows: Fig.49 The comparison between the fitted XRPD diffraction pattern and the measured XRPD diffraction pattern of the crystal obtained by method 1 is shown in Fig.48 As shown, the results show that the composite crystals obtained by method 1 and method 2 are of the same crystalline form.

[0458] 4.4 Crystalline Form of L-Tartrate Salt of the Compound Represented by Formula I-3B

[0459] Method 1: The crystalline form A of the compound represented by formula I-3B and an equimolar amount of tartaric acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of L-tartrate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0460] Method 2: Weigh 299.7 mg of Form A of the compound represented by Formula I-3B and 102.5 mg of an equimolar amount of L-tartaric acid into a 5-mL vial, add 3 mL of acetone / n-heptane (1:1, v:v), suspend and stir at room temperature for 3 days, and centrifuge at room temperature to obtain the crystalline form of L-tartrate of the compound represented by Formula I-3B.

[0461] The XRPD diffraction peak data of the crystal form of the L-tartrate salt of the compound represented by formula I-3B are shown in the following table:

[0462]

[0463]

[0465] The crystal characterization data of the L-tartrate salt of the compound represented by formula I-3B are as follows:

[0466]

[0467]

[0468] The NMR data of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B are as follows:

[0469] # ppm integral 1 8.06 (1H,d) 2 7.83 (1H,d) 3 7.64 (1H,d) 4 6.71 (1H,d) 5 6.60 (1H,dd) 6 4.31 (2H,s) 7 3.92 (1H,d) 8 3.68-3.61 (5H,m) 9 3.50 (3H,s) 10 2.23-2.17 (1H,m) 11 2.12-2.00 (5H,m) 12 1.10-1.06 (2H,m)

[0470] The molar ratio of tartaric acid to the compound represented by formula I-3B is 1.0, and no residual solvent signal is observed in the NMR data.

[0471] 4.5 Crystalline form of p-toluenesulfonate of the compound represented by formula I-3B

[0472] Method 1: The crystalline form A of the compound represented by formula I-3B and an equimolar amount of p-toluenesulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0473] Method 2: 300.9 mg of the crystalline form A of the compound represented by Formula I-3B and 130.8 mg of an equimolar amount of p-toluenesulfonic acid monohydrate were weighed into a 5-mL vial, 3 mL of acetone / n-heptane (1:1, v:v) was added, and the mixture was suspended and stirred at room temperature for 3 days, and centrifuged at room temperature to obtain the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B.

[0474] The XRPD diffraction peak data of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B are shown in the following table:

[0475]

[0476]

[0477]

[0478] The crystal characterization data of the p-toluenesulfonate salt of the compound represented by formula I-3B are as follows:

[0479]

[0481] The crystalline NMR of the p-toluenesulfonate salt of the compound represented by formula I-3B is as follows:

[0482] # ppm integral 1 8.05 (1H,d) 2 7.84 (1H,d) 3 7.65 (1H,d) 4 7.48 (2H,dt) 5 7.12 (2H,d) 6 6.72 (1H,d) 7 6.60 (1H,dd) 8 3.92 (1H,d) 9 3.69-3.61 (5H,m) 10 3.50 (3H,s) 11 2.31 (3H,s) 12 2.23-2.18 (1H,m) 13 2.12-2.00 (5H,m) 14 1.11-1.06 (2H,m)

[0483] The molar ratio of p-toluenesulfonic acid to the compound represented by formula I-3B is 1.0, and no residual solvent signal is observed in the NMR data.

[0484] 4.6 Crystalline Form of L-Malate Salt of the Compound Represented by Formula I-3B

[0485] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of malic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly, and the jelly was subjected to temperature cycle (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain the crystalline form of L-malate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0486] The XRPD diffraction peak data of the crystal form of the L-malate salt of the compound represented by Formula I-3B are shown in the following table:

[0487]

[0488]

[0490] The crystal characterization data of the L-malate salt of the compound represented by formula I-3B are as follows:

[0491]

[0493] The NMR of the crystal form of L-malate of the compound shown in formula I-3B:

[0494]

[0495]

[0496] The signal of malic acid was observed in the NMR data, and the molar ratio of malic acid to the compound represented by formula I-3B was 1.0, and no residual solvent signal was observed.

[0497] 4.7 Crystalline Form A of the Ethylenedisulfonate of the Compound Represented by Formula I-3B

[0498] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in IPA at room temperature for 8 days to obtain the crystalline form of L-malate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0499] The XRPD data of the crystalline form A of the edisylate salt of the compound represented by formula I-3B are as follows:

[0500]

[0502] The characterization data of the crystalline form A of the edisylate salt of the compound represented by formula I-3B are as follows:

[0503]

[0505] The NMR data of the crystalline form A of the edisylate salt of the compound represented by formula I-3B are as follows:

[0506]

[0507]

[0508] According to the NMR data, the molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 0.5, and the molar ratio of solvent IPA to the compound represented by formula I-3B is 0.5 (5.5 wt%).

[0509] 4.8 Form B of the ethanedisulfonate of the compound represented by formula I-3B

[0510] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in IPAc at room temperature overnight to form a jelly, which was then subjected to temperature cycling (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain the crystalline form B of the ethanedisulfonate salt of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0511] The XRPD diffraction peak data of the crystalline form B of the edisylate salt of the compound represented by formula I-3B are shown in the following table:

[0512]

[0513]

[0515] The characterization data of the crystalline form B of the edisylate salt of the compound represented by formula I-3B are as follows:

[0516]

[0518] The NMR data of Form B of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0519] # ppm integral 1 8.06 (1H,d) 2 7.83 (1H,d) 3 7.65 (1H,d) 4 6.71 (1H,d) 5 6.60 (1H,dd) 6 3.92 (1H,d) 7 3.69-3.61 (5H,m) 8 3.50 (3H,d) 9 2.65 (2H,s) 10 2.23-2.18 (1H,m) 11 2.10-2.00 (5H,m) 12 1.11-1.07 (2H,m)

[0520] The molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 0.5, and no residual solvent is observed in the NMR data.

[0521] 4.9 Crystalline Form C of Ethylenedisulfonate of the Compound Represented by Formula I-3B

[0522] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of ethanedisulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly, and the jelly was subjected to temperature cycle (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, a total of 6 cycles) for about 5 days. After volatilization at room temperature, vacuum drying was performed to obtain the crystalline form C of the ethanedisulfonate of the compound represented by formula I-3B, which was characterized at room temperature.

[0523] The XRPD diffraction peak data of the crystalline form C of the edisylate salt of the compound represented by formula I-3B are shown in the following table:

[0524]

[0526] The characterization data of the crystalline form C of the edisylate salt of the compound represented by formula I-3B are as follows:

[0527]

[0528]

[0530] The NMR data of Form C of the edisylate salt of the compound represented by Formula I-3B are as follows:

[0531] # ppm integral 1 8.05 (1H,d) 2 7.85 (1H,d) 3 7.65 (1H,d) 4 6.73 (1H,d) 5 6.60 (1H,dd) 6 3.92 (1H,d) 7 3.69-3.61 (5H,m) 8 3.50 (3H,s) 9 3.23 (1H,m) 10 2.28-2.17 (2H,m) 11 2.12-2.02 (5H,m) 12 1.14-1.06 (2H,m)

[0532] The molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 1.0, the molar ratio of solvent acetone to the compound represented by formula I-3B is 0.3 (2.3wt%), and the molar ratio of solvent n-heptane to the compound represented by formula I-3B is 0.03 (0.5wt%).

[0533] 4.10 Crystalline form of the mesylate salt of the compound represented by formula I-3B

[0534] The crystal form A of the compound shown in formula I-3B and an equimolar amount of methanesulfonic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature overnight to form a jelly, which was subjected to temperature cycling (50°C to 5°C, heating rate 4.5°C / min, constant temperature at 50°C for 2 hours, cooling rate 0.1°C / min, constant temperature at 5°C for 2 hours, a total of 6 cycles) for about 5 days to obtain the crystal form of the mesylate of the compound shown in formula I-3B, which was characterized after vacuum drying at room temperature overnight. The crystal form XRPD diffraction peak data of the mesylate of the compound shown in formula I-3B are shown in the following table:

[0535]

[0536]

[0538] The crystal characterization data of the mesylate salt of the compound represented by formula I-3B are as follows:

[0539]

[0541] The crystal NMR data of the mesylate salt of the compound represented by formula I-3B are as follows:

[0542]

[0543]

[0544] The molar ratio of methanesulfonic acid to the compound represented by formula I-3B is 1.0, and the molar ratio of the residual solvent n-heptane to the compound represented by formula I-3B is 0.008 (0.2 wt%).

[0545] 4.11 Crystalline Form of Benzenesulfonate Salt of the Compound Represented by Formula I-3B

[0546] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of benzenesulfonic acid were suspended and stirred in IPA at room temperature for 8 days to obtain the crystalline form of benzenesulfonate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0547] The XRPD diffraction peak data of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B are shown in the following table:

[0548]

[0549]

[0551] The crystal characterization data of the benzenesulfonate salt of the compound represented by formula I-3B are as follows:

[0552]

[0554] The NMR data of the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B:

[0555]

[0556]

[0557] The molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1.0, and the molar ratio of residual solvent IPA to the compound represented by formula I-3B is 0.01 (0.1 wt%).

[0558] 4.12 Crystalline Form of Oxalate of the Compound Represented by Formula I-3B

[0559] The crystalline form A of the compound represented by formula I-3B and an equimolar amount of oxalic acid were suspended and stirred in acetone / n-heptane (1:1, v:v) at room temperature for 8 days to obtain the crystalline form of the oxalate of the compound represented by formula I-3B, which was characterized after vacuum drying at room temperature overnight.

[0560] The XRPD diffraction peak data of the crystalline form of the oxalate salt of the compound represented by Formula I-3B are shown in the following table:

[0561]

[0562]

[0564] The crystal characterization data of the oxalate salt of the compound represented by formula I-3B are as follows:

[0565]

[0567] The NMR data of the crystalline form of the oxalate salt of the compound represented by formula I-3B are as follows:

[0568]

[0569]

[0570] No residual solvent signal was observed in the NMR data. HPLC / IC results showed that the molar ratio of oxalic acid to the compound represented by formula I-3B was 1.4.

[0571] Effect Example 1 Effect Test of Compound Represented by Formula I-3B

[0572] Use Assay Buffer (50mM Tris-HCl, pH 7.5, 0.01vol% Tween 20) to prepare 15-PGDH (R&D Systems, catalog number 5660-DH-010) to twice the final concentration, i.e. 30nM. Then add it to a 384 white plate (Cisbio Bioassays, catalog number 66PL384025) at 8μl / well. Set up a negative control well, add only Assay Buffer without enzyme. Then use Assay Buffer to prepare the compound to 4 times the final concentration, i.e. 4000nM starting, 3-fold dilution, 10 concentrations. Add it to the above white plate at 4μl / well, mix well, centrifuge at 1000rpm for 1min, and incubate at 25°C for 10min. At the same time, set up a positive control well (only 15-PGDH) and a negative control well (without 15-PGDH). Use Assay Buffer to prepare NAD + (Sellect. Product No. S2518) and PGE 2(R&D Systems, Cat. No. 2296 / 10). + and PGE 2 Prepared to 4 times the final concentration, i.e. 2mM and 0.12mM. Then added to the above white plate at 4μl / well, mixed, centrifuged at 1000rpm for 1min, and incubated at 25℃ for 30min for reaction. TECAN SPARK 20M instrument was used for detection at an excitation wavelength of 340nm and an emission wavelength of 485nm. IC was calculated by four-parameter fitting using GraphPad Prism 8.0 50 value.

[0573] The results of the 15-PGDH inhibition test of the compounds obtained in Example 1

[0574] Compound No. <![CDATA[IC 50 (nM)]]> Compound I-3 4.2 Compound I-3A 12.16 Compound I-3B 3.58

[0575] The experimental results show that the compound of the present invention has a significant inhibitory effect on 15-PGDH.

[0576] Effect Example 2: Effect of Compounds on PGE in the Supernatant of A549 Cells 2 The impact of level

[0577] A549 cells (Punosai, Wuhan) were cultured in F12K + 10% FBS. Cells in good logarithmic phase were selected for the experiment. The cells were digested and counted, and the cells were inoculated into a 24-well plate, 8,000 cells / well. The cells were placed at 37°C and 5% CO 2 Culture in an incubator overnight. After the cells adhere, replace the culture medium containing 0.5% FBS for about 10 hours, add IL-1β to each well (final concentration 20ng / mL, 1mL / well), and set up a control group (no IL-1β is added to the control group). After about 24 hours of IL-1β stimulation, discard the cell culture fluid in each well, and gently wash each well with fresh culture medium containing 0.5% FBS, and then add 400μL of culture medium containing various concentrations of the compound obtained in Example 1 (20nM and 2500nM) to each well for about 12 hours. Collect the supernatant and use an ELISA kit (R&D Systems, Catalog No. KGE004B) to detect PGE 2 .

[0578] The compound obtained in Example 1 increases PGE2 in the supernatant of A549 cells by multiple times as shown in the following table:

[0579] Compound No. / Concentration 20nM Compound I-3A 0.9 Compound I-3B 4.8

[0580] The experimental results show that the compounds of the present invention can significantly increase PGE 2 Generation of.

[0581] Effect Example 3: Pharmacological efficacy experiment on IPF prevention model in mice

[0582] Male mice were adaptively fed for 1-2 weeks and reached the standard weight (25g), and then a certain dose of bleomycin was used to induce an IPF model (idiopathic pulmonary fibrosis model). On the day of modeling, the mice were randomly divided into a model group and a treatment group according to their weight. The treatment group was treated with nintedanib (60 mg / kg, once a day (qd)) and compound I-3B obtained in Example 1 (2.5 mg / kg, twice a day (bid)), and oral gavage was started every day. The vehicle control group was given a blank solvent for 21 consecutive days. During the treatment period, the body weight was measured every 3 days. At the end of the last day of dosing, the animals were euthanized, the lungs were removed from the thyroid cartilage (no perfusion was required), 10% formalin was slowly perfused into the lungs until both lungs were filled, the aorta was ligated and the animals were fixed in 10% formalin at 5-10 times the tissue volume, paraffin tissue sections were made for the left lung, HE staining, Masson Trichrome staining, and the slices were panoramically scanned using a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner for pathological analysis.

[0583] The pathological evaluation indicators of pulmonary fibrosis are shown in the table below.

[0584]

[0585] The summary table of pulmonary fibrosis scores (mean values) is shown in the following table:

[0586]

[0587]

[0588] The experimental results show that the compounds of the present invention can significantly reduce the degree of fibrosis in the IPF prevention model of mice.

[0589] Effect Example 4: Pharmacodynamic Experiment on IPF Treatment Model in Mice

[0590] Male mice were adaptively fed for 1-2 weeks and reached the standard weight (25g), and then an IPF model (idiopathic pulmonary fibrosis model) was induced with a certain dose of bleomycin. On the day of modeling, the mice were randomly divided into a model group and a drug administration group according to their weight. The drug administration group was administered with nintedanib (60 mg / kg, qd), a low dose of compound I-3B obtained in Example 1 (1 mg / kg, bid), and a high dose of compound I-3B obtained in Example 1 (2.5 mg / kg, bid). The mice were orally gavaged every day starting from Day 7, and the vehicle control group was administered with blank vehicle for 14 consecutive days. During the drug administration period, the body weight was measured twice a week. At the end of the last day of dosing, the animals were euthanized, the lungs were removed from the thyroid cartilage (no perfusion was required), 10% formalin was slowly perfused into the lungs until both lungs were filled, the aorta was ligated and the animals were fixed in 10% formalin at 5-10 times the tissue volume, paraffin tissue sections were made for the left lung, HE staining, Masson Trichrome staining, and the slices were panoramically scanned using a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner for pathological analysis.

[0591] The pathological evaluation indicators of pulmonary fibrosis are shown in the following table:

[0592]

[0593]

[0594] Pulmonary fibrosis score summary table (mean) is shown in the table below

[0595] Group Total pulmonary fibrosis score G1sham 0 G2 Model Group 3.68 G3 Nintedanib 2.84 G4 Compound I-3B Low-dose Group 2.74 G4 Compound I-3B High Dose Group 2.6

[0596] The experimental results show that the compounds of the present invention can significantly reduce the degree of fibrosis in the IPF treatment model of mice.

[0597] Effect Example 5: Mouse liver resection and regeneration efficacy experiment

[0598] 8-week-old male C57BL / 6J mice (20-24g) were anesthetized and fixed with the abdomen facing up. The surgical site was shaved and disinfected with iodine. The abdominal transverse incision was about 1.5-2cm, and the abdominal wall arteries on both sides were clamped with hemostatic clips. After opening the abdominal cavity, each liver lobe was freed, and the hepatic hilum of the liver lobe to be removed was ligated with surgical thread. After the color of the liver lobe turned darker, the left lateral lobe and middle lobe of the liver were removed. After cleaning the residual blood in the abdominal cavity, the muscle layer and the fur layer were sutured layer by layer. Pay attention to postoperative care. Drugs were administered on the day of modeling, and 8 animals were killed on the 1st and 3rd day of drug administration, respectively. The intact liver tissue was weighed and compared with the model group to evaluate the effect of drugs on promoting liver regeneration.

[0599] The experimental results show that the compounds of the present invention can significantly promote liver regeneration.

[0600] Effect Example 6: Pharmacokinetics in mice

[0601] The pharmacokinetic properties of the compound obtained in Example 1 in mice were determined according to the following experimental method.

[0602] Three male CD-1 mice were used, with a dose of 10 mg / kg, and the administration route was oral gavage. The solvent was 5% DMSO + 10% Solutol + 85% Saline. The mice were fasted overnight, and blood was collected before administration and 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours after administration. The blood samples were centrifuged at 6800g for 6 minutes at 2-8℃, and the plasma was collected and stored at -80℃. 10μL of plasma at each time point was added to 200μL of methanol containing 100ng / mL internal standard, vortexed and mixed, and centrifuged at 18000g for 7 minutes at 2-8℃. 200μL was transferred to a 96-well sample plate for LC-MS / MS quantitative analysis. The main pharmacokinetic parameters were analyzed by non-compartmental model using WinNonlin 7.0 software.

[0603] Mouse pharmacokinetic data are shown in the table below:

[0604] Compound No. <![CDATA[C max (ng / mL)]]> <![CDATA[AUC (0-t) (mg / mL)]]> Compound I-3 3710 35502 Compound I-3B 4480 33173

[0605] The experimental results show that the compound of the present invention exhibits excellent pharmacokinetic properties in mice.

[0606] Effect Example 7: IBD efficacy in mice

[0607] Female C57BL / 6 mice aged 6-8 weeks were divided into 5 groups, G1-G5 were normal control group, model control group, positive control group, low-dose group of compound I-3B obtained in Example 1 and high-dose group of compound I-3B obtained in Example 1, respectively. The mice in groups G2-G6 drank a 2% DSS aqueous solution on days 0-6, drank normal water on days 0-10, and were given vehicle / positive / test substances on days 0-9. After euthanasia on day 10, the intestinal weight (CW) and intestinal length (CL) were measured and the intestinal tissue (BW) was subjected to histopathological examination. The test results showed that compared with the animals in the G2 model group, the weight of the animals in the G3-positive control group (cyclosporine CsA 25mg / kg-qd) increased significantly, the DAI of the model animals decreased significantly, the CL increased significantly, the CW, CL / CW / BW and CL / CW decreased significantly, and the results of colonic tissue pathology of the model animals showed that the inflammatory cell infiltration and tissue damage scores decreased, but there was no significant difference. The body weight of animals in the G4-Compound I-3B (2.5 mg / kg-bid) and G5-Compound I-3B (5 mg / kg-bid) groups increased, with the body weight of G5 animals increasing significantly; the DAI of the animals decreased significantly, the CL increased significantly, and the CW, CL / CW / BW and CL / CW decreased significantly; the results of colon tissue pathology showed that the inflammatory cell infiltration and tissue damage scores decreased significantly.

[0608] The colon length (CL), colon weight (CW), CL / CW / BW, and CW / CL of each group of animals are summarized in the following table:

[0609]

[0610] The experimental results showed that compound I-3B (2.5 mg / kg and 5 mg / kg) can significantly improve IBD symptoms and tissue damage in mice, and its therapeutic effect is better than that of positive control.

[0611] Effect Example 8: Crystalline Dynamic Solubility Stability Test

[0612] The crystal form A of the compound represented by Formula I-3B and the crystal form of the fumaric acid complex of the compound represented by Formula I-3B were tested at 37°C. 2 Dynamic solubility in O, SGF, FaSSIF, and FeSSIF.

[0613] The above sample was mixed at a concentration of 10 mg / mL (based on the compound shown in Formula I-3B) at 37°C, and the solubility of each sample was measured at different time points (1, 4 and 24 hours). After sampling at each time point, the samples were centrifuged (12000 rpm, 2 min) and filtered (0.45 μm PTFE membrane), and the HPLC concentration and pH value of the filtrate were measured. The solid sample after centrifugation was tested by XRPD.

[0614] The results of the dynamic solubility test are shown in the following table:

[0615]

[0616]

[0617] S: concentration of the compound represented by formula I-3B (mg / mL); FC: crystal transformation, --: not tested.

[0618] The results show that the crystalline form A of the compound shown in formula I-3B and the crystalline form of the fumaric acid complex of the compound shown in formula I-3B have good solubility in various solvents. Fig.32 , 33 , 34, 35, 36, 37, 38 and 39. By comparing the data of the initial, 1 hour, 4 hours and 24 hours of the test of each sample, it can be seen that the crystal form A of the compound represented by Formula I-3B and the crystal form solid of the fumaric acid complex of the compound represented by Formula I-3B did not undergo any crystal form change in the tests of each system, indicating that they have good stability.

[0619] Effect Example 9: Solid-state stability evaluation experiment

[0620] The samples of crystalline form A of the compound shown in formula I-3B, crystalline form B of the compound shown in formula I-3B, crystalline form of the fumaric acid complex of the compound shown in formula I-3B, and crystalline form of the tartrate salt of the compound shown in formula I-3B were placed under the conditions of 60°C / closed / 1 day, 25°C / 60% RH / open / 1 week, and 40°C / 75% RH / open / 1 week, respectively, and their physical and chemical stabilities were evaluated by XRPD and HPLC.

[0621] The purity and stability test data of the samples are as follows:

[0622]

[0623] The HPLC test data of the crystalline form A of the compound represented by formula I-3B are as follows:

[0624]

[0625] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0626] The HPLC test data of the crystalline form B of the compound represented by formula I-3B are as follows:

[0627]

[0628] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0629] The HPLC test data of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B are as follows:

[0630]

[0631] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0632] The HPLC test data of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B are as follows:

[0633]

[0634] Note: The relative retention time of 1 min corresponds to the compound represented by sample formula I-3B.

[0635] XRPD results are listed in Fig.40 , 41 , 42 and 43. The results showed that the purity of each tested crystal form was good after being placed for a period of time, and basically the HPLC purity did not change significantly. No crystal form change was observed in each tested crystal form, indicating that it has high stability.

[0636] Effect Example 10: Moisture-attracting Test

[0637] DVS was used to evaluate the hygroscopicity of the crystalline form A of the compound shown in Formula I-3B, the crystalline form B of the compound shown in Formula I-3B, the crystalline form of the fumaric acid complex of the compound shown in Formula I-3B, and the crystalline form of the tartrate salt of the compound shown in Formula I-3B.

[0638] The results show that the test samples have good hygroscopicity. The XRPD results of the samples after DVS test are listed in Fig.44 , 45 , 46 and 47, comparing the data before and after the DVS test, the hygroscopicity evaluation results show that the crystalline form A of the compound shown in Formula I-3B has a moisture absorption weight gain of 1.112% at 25°C / 80%RH, and there is no change in the crystalline form after the test; the crystalline form B of the compound shown in Formula I-3B has a moisture absorption weight gain of 0.1309% at 25°C / 80%RH, the sample has no hygroscopicity, and there is no change in the crystalline form after the test; the crystalline form of the fumaric acid complex of the compound shown in Formula I-3B has a moisture absorption weight gain of 0.0880% at 25°C / 80%RH, the sample has no hygroscopicity, and there is no change in the crystalline form after the test; the crystalline form of the tartrate salt of the compound shown in Formula I-3B has a moisture absorption weight gain of 0.2291% at 25°C / 80%RH, the sample has a slight hygroscopicity, and there is no change in the crystalline form after the test.

[0639] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A pharmaceutically acceptable salt of a heterocyclic compound or a solvate thereof, It is characterized in that The heterocyclic compound is a compound represented by formula I-3A and / or a compound represented by formula I-3B; Wherein, the pharmaceutically acceptable salt is a salt formed by a heterocyclic compound and an acid; the acid is selected from hydrochloric acid, phosphoric acid, fumaric acid, tartaric acid, malic acid, ethanedisulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or oxalic acid.

2. A pharmaceutically acceptable salt or solvate of the heterocyclic compound according to claim 1, It is characterized in that The pharmaceutically acceptable salt of the heterocyclic compound or its solvate satisfies one or more of the following conditions: (1) In the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the solvent is selected from one or two of isopropyl acetate, acetone, isopropanol and n-heptane; (2) When the heterocyclic compound is a compound represented by formula I-3A or a compound represented by formula I-3B, it is a compound represented by formula I-3: (3) In the pharmaceutically acceptable salt of the heterocyclic compound or a solvate thereof, the molar ratio of the heterocyclic compound to the acid is 1:(0.5-2), such as 1:(0.5-1), and further such as 1:1, 1:0.9 or 1:0.5; (4) The heterocyclic compound is a compound represented by formula I-3B (5) the solvate of the pharmaceutically acceptable salt of the heterocyclic compound is not the monohydrochloride monohydrate of the heterocyclic compound; and (6) In the solvate of the pharmaceutically acceptable salt of the heterocyclic compound, the molar ratio of the heterocyclic compound to the solvent is 1:(0.001-2), for example 1:(0.001-1), for example 1:0.05, 1:0.9, 1:0.01, 1:0.04, 1:0.008, 1:0.03, 1:0.3 or 1:0.

5.

3. A pharmaceutically acceptable salt or solvate of the heterocyclic compound according to claim 1, It is characterized in that The pharmaceutically acceptable salt or solvate of the heterocyclic compound is: The compound of formula I-3B: the hydrochloride acetone solvate of the compound of formula I-3B, wherein the molar ratio of hydrochloric acid, the compound of formula I-3B and acetone is 0.9:1:0.9; Or, a phosphate of the compound of formula I-3B, wherein the molar ratio of phosphoric acid to the compound of formula I-3B is 1:1; Or, a phosphate acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of phosphoric acid, the compound represented by formula I-3B and acetone is 1:1:0.05; Or, a fumarate salt of the compound represented by formula I-3B, wherein the molar ratio of fumaric acid to the compound represented by formula I-3B is 1:1; Or, L-tartrate of the compound of formula I-3B, wherein the molar ratio of tartaric acid to the compound of formula I-3B is 1:1; Or, L-malate of the compound of formula I-3B, wherein the molar ratio of malic acid to the compound of formula I-3B is 1:1; Or, an isopropanol solvate of an edisulphonate of the compound of formula I-3B, wherein the molar ratio of edisulphonic acid, the compound of formula I-3B and isopropanol is 0.5:1:0.5; Or, ethanedisulfonate of the compound represented by formula I-3B, wherein the molar ratio of ethanedisulfonic acid to the compound represented by formula I-3B is 0.5:1; Or, an edisulphonate of the compound represented by formula I-3B, wherein the molar ratio of edisulphonic acid to the compound represented by formula I-3B is 1:1; Or, ethanedisulfonic acid salt of the compound represented by formula I-3B and acetone n-heptane solvate, wherein the molar ratio of ethanedisulfonic acid, the compound represented by formula I-3B, acetone and n-heptane is 1:1:0.3:0.03; Or, p-toluenesulfonate of the compound represented by formula I-3B, wherein the molar ratio of p-toluenesulfonate to the compound represented by formula I-3B is 1:1; Or, a methanesulfonate salt of the compound of formula I-3B, wherein the molar ratio of methanesulfonic acid to the compound of formula I-3B is 1:1; Or, a methanesulfonate n-heptane solvate of the compound represented by formula I-3B, wherein the molar ratio of methanesulfonic acid, the compound represented by formula I-3B and n-heptane is 1:1:0.008; Or, a benzenesulfonate salt of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid to the compound represented by formula I-3B is 1:1; Or, a benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of benzenesulfonic acid, the compound represented by formula I-3B and isopropanol is 1:1:0.01; Or, an oxalate of the compound represented by formula I-3B, wherein the molar ratio of oxalic acid to the compound represented by formula I-3B is 1:

1.

4. A crystal form, which is the crystal form A of the compound shown in formula I-3B, the crystal form B of the compound shown in formula I-3B, the crystal form of the hydrochloride of the compound shown in formula I-3B, the crystal form of the phosphate of the compound shown in formula I-3B, the crystal form of the fumaric acid complex of the compound shown in formula I-3B, the crystal form of the L-tartrate of the compound shown in formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in formula I-3B, the crystal form of the L-malate of the compound shown in formula I-3B, the crystal form A of the edisylate of the compound shown in formula I-3B, the crystal form B of the edisylate of the compound shown in formula I-3B, the crystal form C of the edisylate of the compound shown in formula I-3B, the crystal form of the methanesulfonate of the compound shown in formula I-3B, the crystal form of the benzenesulfonate of the compound shown in formula I-3B, or the crystal form of the oxalate of the compound shown in formula I-3B; in, The structure of the compound shown in formula I-3B is: The crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 18.6±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2° and 14.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2° and 11.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2° and 11.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2° and 22.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2° and 23.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at 6.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2° and 22.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2° and 18.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; The crystalline form of the methanesulfonate of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2° and 21.8±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2° and 21.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; The crystalline form of the oxalate salt of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2° and 16.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation.

5. The crystal form according to claim 4, It is characterized in that It meets one or more of the following conditions: (1) The crystalline form A of the compound represented by the formula I-3B has an X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 23.1±0.2°, 17.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2°; For example, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 18.6±0.2° and 11.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form A of the compound represented by the formula I-3B has diffraction peaks at 15.2±0.2°, 22.8±0.2°, 19.1±0.2°, 17.6±0.2°, 21.6±0.2°, 23.1±0.2°, 18.6±0.2°, 11.9±0.2°, 24.9±0.2° and 20.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (2) The X-ray powder diffraction pattern of the crystalline form B of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles also has diffraction peaks at one or more of the following positions: 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2°; For example, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form B of the compound represented by the formula I-3B has diffraction peaks at 18.5±0.2°, 24.8±0.2°, 21.6±0.2°, 20.9±0.2°, 14.4±0.2°, 14.9±0.2°, 19.2±0.2°, 17.7±0.2°, 17.1±0.2° and 15.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (3) In the crystalline form of the hydrochloride of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to hydrochloric acid is 1:0.9; Alternatively, the crystalline form of the hydrochloride of the compound represented by formula I-3B is a crystalline form of the hydrochloride acetone solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, hydrochloric acid and acetone is 1:0.9:0.9; (4) The crystalline form of the hydrochloride of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2°; For example, the crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2° and 20.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form of the hydrochloride of the compound represented by the formula I-3B has diffraction peaks at 9.5±0.2°, 24.8±0.2°, 17.3±0.2°, 19.3±0.2°, 11.7±0.2°, 20.7±0.2°, 18.9±0.2°, 22.8±0.2°, 6.6±0.2° and 22.7±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (5) In the crystal form of the phosphate of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to phosphoric acid is 1:0.9; Alternatively, the crystal form of the phosphate of the compound of formula I-3B is a crystal form of phosphate acetone solvate of the compound of formula I-3B, wherein the molar ratio of the compound of formula I-3B, phosphoric acid and acetone is 1:0.9:0.05; (6) The phosphate of the compound of formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at one or more of the following locations: 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2°; For example, the crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2° and 19.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form of the phosphate of the compound represented by the formula I-3B has diffraction peaks at 16.7±0.2°, 16.3±0.2°, 8.3±0.2°, 21.1±0.2°, 11.5±0.2°, 23.2±0.2°, 19.2±0.2°, 20.1±0.2°, 22.3±0.2° and 10.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (7) The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2°; For example, the crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2° and 26.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has diffraction peaks at 20.5±0.2°, 15.9±0.2°, 26.6±0.2°, 18.9±0.2°, 22.5±0.2°, 22.3±0.2°, 26.4±0.2°, 10.8±0.2°, 17.4±0.2° and 17.5±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (8) The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2°; For example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2° and 18.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has diffraction peaks at 8.2±0.2°, 20.7±0.2°, 20.1±0.2°, 15.7±0.2°, 23.3±0.2°, 18.4±0.2°, 9.6±0.2°, 17.6±0.2°, 21.3±0.2° and 23.0±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (9) The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2°; For example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2° and 20.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 6.6±0.2°, 19.8±0.2°, 18.5±0.2°, 19.7±0.2°, 20.4±0.2°, 9.8±0.2°, 11.4±0.2°, 13.2±0.2°, 22.3±0.2° and 8.1±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (10) The crystalline form of the L-malate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2°; For example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2° and 17.2±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B has diffraction peaks at 15.8±0.2°, 20.3±0.2°, 18.8±0.2°, 21.8±0.2°, 22.0±0.2°, 20.6±0.2°, 25.5±0.2°, 17.2±0.2°, 16.1±0.2° and 17.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (11) In the crystalline form A of the ethanedisulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:0.5; Alternatively, the crystalline form A of the edisulphonate of the compound represented by formula I-3B is a crystalline form of the edisulphonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, edisulphonic acid and isopropanol is 1:0.5:0.5; (12) The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2°; For example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2° and 21.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angle using Cu-Kα radiation; For another example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 5.3±0.2°, 18.9±0.2°, 20.1±0.2°, 21.0±0.2°, 18.2±0.2°, 21.6±0.2°, 17.4±0.2°, 22.3±0.2° and 11.5±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (13) The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2°; For example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2° and 15.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 18.6±0.2°, 19.4±0.2°, 21.6±0.2°, 17.7±0.2°, 22.1±0.2°, 15.1±0.2°, 6.3±0.2°, 20.8±0.2°, 20.4±0.2° and 11.0±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (14) In the crystalline form C of the ethanedisulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to ethanedisulfonic acid is 1:1; Alternatively, the crystalline form C of the edisylate salt of the compound represented by formula I-3B is a crystalline form of edisylate salt of the compound represented by formula I-3B acetone n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, edisylic acid, acetone and n-heptane is 1:1:03:0.03; (15) The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles, and has diffraction peaks at one or more of the following positions: 7.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2°; For example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2° and 17.3±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B has diffraction peaks at 20.3±0.2°, 19.6±0.2°, 11.6±0.2°, 24.0±0.2°, 23.0±0.2°, 17.3±0.2°, 23.2±0.2°, 13.0±0.2°, 16.4±0.2° and 15.4±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (16) In the crystalline form of the methanesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to methanesulfonic acid is 1:1; Alternatively, the crystalline form of the methanesulfonate of the compound represented by formula I-3B is a crystalline form of the methanesulfonate of the compound represented by formula I-3B n-heptane solvate, wherein the molar ratio of the compound represented by formula I-3B, methanesulfonic acid and n-heptane is 1:1:0.008; (17) The crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2°; For example, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2° and 15.6±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 9.4±0.2°, 6.5±0.2°, 19.9±0.2°, 18.2±0.2°, 21.8±0.2°, 18.6±0.2°, 15.6±0.2°, 7.6±0.2°, 22.2±0.2° and 16.9±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (18) In the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to benzenesulfonic acid is 1:1; Alternatively, the crystalline form of the benzenesulfonate salt of the compound represented by formula I-3B is a crystalline form of the benzenesulfonate isopropanol solvate of the compound represented by formula I-3B, wherein the molar ratio of the compound represented by formula I-3B, benzenesulfonic acid and isopropanol is 1:1:0.01; (19) The benzenesulfonate salt of the compound represented by the formula I-3B has a X-ray powder diffraction pattern using Cu-Kα radiation and expressed in 2θ angles at one or more of the following locations: 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2°; For example, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, and 19.1±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has diffraction peaks at 21.4±0.2°, 20.0±0.2°, 19.6±0.2°, 15.1±0.2°, 21.0±0.2°, 20.5±0.2°, 19.1±0.2°, 21.2±0.2°, 6.9±0.2° and 10.6±0.2° using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles; (20) The crystalline form of the oxalate salt of the compound represented by the formula I-3B has a diffraction peak at one or more of the following positions using Cu-Kα radiation and expressed in 2θ angles: 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2°; For example, the crystalline form of the oxalate of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2° and 15.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; For another example, the crystalline form of the oxalate of the compound represented by the formula I-3B has diffraction peaks at 27.7±0.2°, 7.8±0.2°, 15.7±0.2°, 17.1±0.2°, 16.5±0.2°, 19.2±0.2°, 15.4±0.2°, 23.6±0.2° and 22.4±0.2° in an X-ray powder diffraction pattern expressed in 2θ angles using Cu-Kα radiation; (21) The crystalline form A of the compound represented by formula I-3B is a crystalline form of an isopropyl acetate solvate of the compound represented by formula I-3B, and the molar ratio of the compound represented by formula I-3B to the isopropyl acetate is 1:0.04; (22) In the crystalline form of the fumaric acid complex of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to fumaric acid is 1:1; Preferably, the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is a fumaric acid cocrystal of the compound represented by formula I-3B; (23) In the crystalline form of the L-tartrate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-tartaric acid is 1:1; (24) In the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to p-toluenesulfonic acid is 1:1; (25) In the crystalline form of the L-malate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to L-malic acid is 1:1; (26) In the crystalline form B of the edisylate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to edisylic acid is 1:0.5; and (27) In the crystal form of the oxalate salt of the compound represented by formula I-3B, the molar ratio of the compound represented by formula I-3B to oxalic acid is 1:

1.

6. The crystal form according to claim 4, It is characterized in that The crystal form satisfies one or more of the following conditions: (1) The X-ray powder diffraction pattern of the crystalline form A of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 1: Table 1 For example, the crystalline form A of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG1 ; (2) The differential scanning calorimetry curve of the crystalline form A of the compound represented by formula I-3B has an endothermic peak starting point at 160.9±3°C, and / or the differential scanning calorimetry curve of the crystalline form A of the compound represented by formula I-3B reaches an endothermic peak at 168.4±3°C; For example, the differential scanning calorimetry curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 ; (3) The thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B shows a weight loss of approximately 0.67% in the temperature range of 14.8±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of Form A of the compound represented by Formula I-3B is substantially as shown in FIG2 ; (4) The X-ray powder diffraction pattern of the crystalline form B of the compound represented by the formula I-3B using Cu-Kα radiation and expressed in 2θ angles has the diffraction peaks shown in Table 2: Table 2 For example, the crystal form B of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG4 ; (5) The differential scanning calorimetry curve of the crystalline form B of the compound represented by formula I-3B has an endothermic peak starting point at about 164.2±3°C, and / or the differential scanning calorimetry curve of the crystalline form B of the compound represented by formula I-3B reaches an endothermic peak at about 171.7±3°C; For example, the differential scanning calorimetry curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 ; (6) The thermogravimetric analysis curve of Form B of the compound represented by Formula I-3B shows a weight loss of approximately 1.61% in the temperature range of 26.6±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of Form B of the compound represented by Formula I-3B is substantially as shown in FIG5 ; (7) The crystalline form of the hydrochloride of the compound represented by the formula I-3B has a diffraction peak as shown in Table 3 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 3 For example, the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG7 ; (8) The differential scanning calorimetry curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B reaches endothermic peaks at 122.1±3°C and 199.6±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 ; (9) The thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by the formula I-3B shows a weight loss of about 13.39% in the temperature range of 17.7±3°C to 100°C±3°C, and a weight loss of about 4.54% in the temperature range of 100±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the hydrochloride salt of the compound represented by Formula I-3B is substantially as shown in FIG8 ; (10) The crystal form of the phosphate of the compound represented by the formula I-3B has a diffraction peak shown in Table 4 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 4 For example, the crystal form of the phosphate of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG9 ; (11) The differential scanning calorimetry curve of the crystalline form of the phosphate of the compound represented by formula I-3B reaches the peak of the endothermic peak at 158.5±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the phosphate salt of the compound represented by formula I-3B is substantially as shown in FIG10 ; (12) The thermogravimetric analysis curve of the crystalline form of the phosphate of the compound represented by formula I-3B shows a weight loss of about 2.07% in the temperature range of 27.4±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the phosphate of the compound represented by formula I-3B is substantially as shown in FIG. 10 (13) The crystalline form of the fumaric acid complex of the compound represented by the formula I-3B has a diffraction peak as shown in Table 5 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 5 For example, the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG11 ; (14) The differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B has an endothermic peak starting point at 165.2±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by formula I-3B reaches an endothermic peak at 167.2±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 ; (15) The thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B shows a weight loss of about 0.36% in the temperature range of 26.2±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the fumaric acid complex of the compound represented by Formula I-3B is substantially as shown in FIG12 ; (16) The crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 6 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 6 For example, the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG13 ; (17) The differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 162.4±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by the formula I-3B reaches an endothermic peak at 165.7±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the L-tartrate salt of the compound represented by formula I-3B is substantially as shown in FIG14 ; (18) The thermogravimetric analysis curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B shows a weight loss of about 0.57% in the temperature range of 25.9±3°C to 120°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the L-tartrate salt of the compound represented by Formula I-3B is substantially as shown in FIG14 ; (19) The crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 7 using Cu-Kα radiation and expressed in 2θ angles: Table 7 For example, the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG15 ; (20) The differential scanning calorimetry curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by the formula I-3B reaches the peak of the endothermic peak at 278.9±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 ; (21) The thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 0.89% in the temperature range of 25.9±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the p-toluenesulfonate salt of the compound represented by Formula I-3B is shown in FIG16 ; (22) The crystalline form of the L-malate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 8 using Cu-Kα radiation and expressed in 2θ angles: Table 8 For example, the crystalline form of the L-malate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG17 ; (23) The differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 120.4±3°C, and / or, the differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by the formula I-3B reaches endothermic peaks at 128.1±3°C and 213.6±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 ; (24) The thermogravimetric analysis curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B shows a weight loss of approximately 1.31% in the temperature range of 27.5±3°C to 100°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the L-malate salt of the compound represented by Formula I-3B is substantially as shown in FIG18 ; (25) The crystalline form A of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 9 using Cu-Kα radiation and expressed in 2θ angles: Table 9 For example, the crystalline form A of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG19 ; (26) The differential scanning calorimetry curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B reaches the peak values ​​of the endothermic peaks at 162.8±3°C and 239.7±3°C, and reaches the peak value of the exothermic peak at 198.8±3°C; For example, the differential scanning calorimetry curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B is substantially as shown in FIG20 ; (27) The thermogravimetric analysis curve of the crystalline form A of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 9.08% in the temperature range of 25.2±3°C to 170°C±3°C; For example, the thermogravimetric analysis curve of Form A of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG20 ; (28) The crystalline form B of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 10 using Cu-Kα radiation and expressed in 2θ angles: Table 10 For example, the crystalline form B of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG21 ; (29) The differential scanning calorimetry curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B has an endothermic peak starting point at 235.8±3°C, and / or the differential scanning calorimetry (DSC) curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B reaches an endothermic peak at 242.4±3°C; For example, the differential scanning calorimetry curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B is substantially as shown in FIG22 ; (30) The thermogravimetric analysis curve of the crystalline form B of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 1.84% in the temperature range of 28.4±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of Form B of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG22 ; (31) The crystalline form C of the edisylate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 11 using Cu-Kα radiation and expressed in 2θ angles: Table 11 For example, the crystalline form C of the edisylate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG23 ; (32) The differential scanning calorimetry curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B reaches endothermic peaks at 109.5±3°C and 243.6±3°C; For example, the differential scanning calorimetry curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG24 ; (33) The thermogravimetric analysis curve of the crystalline form C of the edisylate salt of the compound represented by formula I-3B shows a weight loss of about 7.28% in the temperature range of 28.6±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of Form C of the edisylate salt of the compound represented by Formula I-3B is substantially as shown in FIG24 ; (34) The crystalline form of the methanesulfonate of the compound represented by the formula I-3B has a diffraction peak shown in Table 12 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 12 For example, the crystalline form of the mesylate salt of the compound represented by the formula I-3B is irradiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG25 ; (35) The differential scanning calorimetry curve of the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B has an endothermic peak starting point at 116.3±3°C, and / or the differential scanning calorimetry curve of the crystalline form of the methanesulfonate salt of the compound represented by the formula I-3B reaches an endothermic peak at 124.3±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the mesylate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 ; (36) The thermogravimetric analysis curve of the crystalline form of the methanesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 4.53% in the temperature range of 28.4±3°C to 80°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the mesylate salt of the compound represented by Formula I-3B is substantially as shown in FIG26 ; (37) The crystalline form of the benzenesulfonate salt of the compound represented by the formula I-3B has a diffraction peak shown in Table 13 using Cu-Kα radiation and an X-ray powder diffraction pattern expressed in 2θ angles: Table 13 For example, the benzenesulfonate salt of the compound represented by Formula I-3B is radiated with Cu-Kα, and its X-ray powder diffraction pattern is substantially as shown in FIG27 ; (38) The differential scanning calorimetry curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B reaches the peak of the endothermic peak at 254.1±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 ; (39) The thermogravimetric analysis curve of the benzenesulfonate salt of the compound represented by Formula I-3B shows a weight loss of about 1.32% in the temperature range of 28.4±3°C to 150°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the benzenesulfonate salt of the compound represented by Formula I-3B is substantially as shown in FIG28 ; (40) The crystalline form of the oxalate salt of the compound represented by the formula I-3B has a diffraction peak as shown in Table 14 using Cu-Kα radiation and expressed in 2θ angles: Table 14 For example, the crystalline form of the oxalate salt of the compound represented by the formula I-3B uses Cu-Kα radiation, and its X-ray powder diffraction pattern is substantially as shown in FIG29 ; (41) The differential scanning calorimetry curve of the crystalline form of the oxalate salt of the compound represented by formula I-3B reaches endothermic peaks at 129.7±3°C and 198.2±3°C; For example, the differential scanning calorimetry curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG30 ; and (42) The thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by the formula I-3B shows a weight loss of about 2.27% in the temperature range of 28.4±3°C to 100°C±3°C; For example, the thermogravimetric analysis curve of the crystalline form of the oxalate salt of the compound represented by Formula I-3B is substantially as shown in FIG. 30 .

7. The crystal form according to claim 4, It is characterized in that The crystal form of the fumaric acid complex of the compound represented by formula I-3B has the following unit cell parameters: orthorhombic system, space group P2 1 2 1 2 1 ; α=90°, β=90°, γ=90°, The number of asymmetric units in the unit cell is Z = 4, and the crystal density is 1.451 mg / m 3 .

8. A method for preparing the crystal form according to any one of claims 4 to 6, It is characterized in that It is either method one or method two: Method 1: The preparation method comprises the following steps: crystallizing a mixture of the compound represented by formula I-3B and a solution to obtain a crystalline form of the compound represented by formula I-3B or a solvate thereof; In method 1, when the crystalline form A of the compound represented by formula I-3B is obtained, the solvent is isopropyl acetate; When the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is one or more of methanol, water, acetonitrile and methyl tert-butyl ether; Method 2: The preparation method comprises the following steps: crystallizing a mixture of the compound represented by formula I-3B, an acid and a solvent; In method 2, when the crystalline form of the hydrochloride salt of the compound represented by formula I-3B is obtained, the acid is hydrochloric acid and the solvent is acetone; When the crystalline form of the phosphate of the compound represented by formula I-3B is obtained, the acid is phosphoric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the fumaric acid complex of the compound represented by formula I-3B is obtained, the acid is fumaric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of L-tartrate of the compound represented by formula I-3B is obtained, the acid is tartaric acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the p-toluenesulfonate salt of the compound represented by formula I-3B is obtained, the acid is p-toluenesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystal form of L-malate of the compound represented by formula I-3B is obtained, the acid is malic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form A of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropanol; When the crystalline form B of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid and the solvent is isopropyl acetate; When the crystalline form C of the edisylate salt of the compound represented by formula I-3B is obtained, the acid is edisylic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of the mesylate salt of the compound represented by formula I-3B is obtained, the acid is methanesulfonic acid, and the solvent is a mixed solution of acetone and n-heptane; When the crystalline form of benzenesulfonate of the compound represented by formula I-3B is obtained, the acid is benzenesulfonic acid and the solvent is isopropanol; When the crystalline form of the oxalate of the compound represented by formula I-3B is obtained, the acid is oxalic acid, and the solvent is a mixed solution of acetone and n-heptane; Preferably, the preparation method meets one or more of the following conditions: (1) In the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the solvent is a mixed solution of methanol and water or a mixed solution of acetonitrile and methyl tert-butyl ether, preferably a mixed solution of methanol and water with a volume ratio of methanol to water of 1:5; Alternatively, in the method for preparing the crystalline form of the compound shown in Formula I-3B, when the crystalline form A of the compound shown in Formula I-3B is obtained, the crystallization is to cool the mixture of isopropyl acetate and the compound shown in Formula I-3B to room temperature and dry to obtain the crystalline form A of the compound shown in Formula I-3B; (2) In the method for preparing the crystalline form of the compound represented by formula I-3B, when the crystalline form B of the compound represented by formula I-3B is obtained, the crystallization is to crystallize the compound represented by formula I-3B and a mixture of methanol and water at 50° C., and dry to obtain the crystalline form B of the compound represented by formula I-3B; (3) In the preparation method, when the solvent is a mixed solution of acetone and n-heptane, the volume ratio of acetone to n-heptane is 1:1; (4) In the preparation method, the molar ratio of the compound represented by formula I-3B to the acid is 1:1; and (5) The preparation method comprises the following steps: suspending the compound represented by formula I-3B, an acid and a solvent to obtain a mixture, and crystallizing to obtain a crystalline form of a pharmaceutically acceptable salt of the compound represented by formula I-3B; Preferably, in the preparation method, when the obtained product is a crystalline form of hydrochloride of the compound of formula I-3B, a crystalline form of L-malate of the compound of formula I-3B, a crystalline form B of edisylate of the compound of formula I-3B, a crystalline form C of edisylate of the compound of formula I-3B, a crystalline form of methanesulfonate of the compound of formula I-3B or a crystalline form of benzenesulfonate of the compound of formula I-3B, the crystallization comprises the following steps: subjecting the mixture of the compound of formula I-3B, acid and solvent to temperature cycling and drying; Alternatively, in the preparation method, when the crystal form of the phosphate of the compound shown in Formula I-3B, the crystal form of the fumaric acid complex of the compound shown in Formula I-3B, the crystal form of the L-tartrate of the compound shown in Formula I-3B, the crystal form of the p-toluenesulfonate of the compound shown in Formula I-3B, the crystal form A of the ethanedisulfonate of the compound shown in Formula I-3B, or the crystal form of the oxalate of the compound shown in Formula I-3B is obtained, the crystallization comprises the following steps: drying the mixture of the compound shown in Formula I-3B, acid and solvent.

9. A pharmaceutical composition, wherein the pharmaceutical composition is any of the following: Solution 1: The pharmaceutical composition comprises a pharmaceutically acceptable salt or a solvate thereof of the heterocyclic compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier; Option 2: The pharmaceutical composition comprises a substance X and a pharmaceutically acceptable carrier, wherein the substance X is a crystalline form A of the compound shown in formula I-3B according to any one of claims 4 to 7, a crystalline form B of the compound shown in formula I-3B, a crystalline form of the hydrochloride of the compound shown in formula I-3B, a crystalline form of the phosphate of the compound shown in formula I-3B, a crystalline form of the fumaric acid complex of the compound shown in formula I-3B, a crystalline form of the L-tartrate of the compound shown in formula I-3B, a crystalline form of the p-toluenesulfonate of the compound shown in formula I-3B, a crystalline form of the L-malate of the compound shown in formula I-3B, a crystalline form A of the edisylate of the compound shown in formula I-3B, a crystalline form B of the edisylate of the compound shown in formula I-3B, a crystalline form C of the edisylate of the compound shown in formula I-3B, a crystalline form of the methanesulfonate of the compound shown in formula I-3B, a crystalline form of the benzenesulfonate of the compound shown in formula I-3B, or a crystalline form of the oxalate of the compound shown in formula I-3B.

10. Application of a substance, It is characterized in that The substance is a pharmaceutically acceptable salt of a heterocyclic compound according to any one of claims 1 to 3 or a solvate thereof, a pharmaceutical composition according to claim 9 or a substance X; The substance X is the crystal form A of the compound of formula I-3B according to any one of claims 4 to 7, the crystal form B of the compound of formula I-3B, the crystal form of the hydrochloride of the compound of formula I-3B, the crystal form of the phosphate of the compound of formula I-3B, the crystal form of the fumaric acid complex of the compound of formula I-3B, the crystal form of the L-tartrate of the compound of formula I-3B, the crystal form of the p-toluenesulfonate of the compound of formula I-3B, the crystal form of the L-malate of the compound of formula I-3B, the crystal form A of the edisylate of the compound of formula I-3B, the crystal form B of the edisylate of the compound of formula I-3B, the crystal form C of the edisylate of the compound of formula I-3B, the crystal form of the methanesulfonate of the compound of formula I-3B, the crystal form of the benzenesulfonate of the compound of formula I-3B, or the crystal form of the oxalate of the compound of formula I-3B; The application includes: preparing a 15-PGDH inhibitor, and / or preparing a medicine, a pharmaceutical composition or a preparation for preventing and / or treating a disease related to 15-PGDH.

11. Use of a substance as claimed in claim 10, It is characterized in that The 15-PGDH-related disease is one, two or more of fibrotic disease, inflammatory disease, cardiovascular disease, trauma, autoimmune disease, graft-versus-host disease, hair growth, osteoporosis, ear disease, eye disease, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstruction, tissue damage, cervical disease or kidney disease; preferably one or more of fibrosis, inflammatory disease or tissue damage; Preferably, the 15-PGDH-related disease further satisfies one or more of the following conditions: (1) The fibrotic disease is one or more of pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis, scleroderma or myelofibrosis, preferably pulmonary fibrosis and / or liver fibrosis, such as pulmonary fibrosis; for example, the pulmonary fibrosis may be idiopathic pulmonary fibrosis; (2) The inflammatory disease is one or more of chronic obstructive pulmonary disease, acute lung injury, sepsis, asthma and exacerbation of lung disease, inflammatory bowel disease, peptic ulcer, autoinflammatory disease, vasculitis syndrome, acute liver injury, acute kidney injury, non-alcoholic fatty liver disease, atopic dermatitis, psoriasis, interstitial cystitis or prostatitis syndrome, preferably inflammatory bowel disease; for example, the inflammatory bowel disease may be ulcerative colitis and / or Crohn's disease; the peptic ulcer may be an NSAID-induced ulcer; the autoinflammatory disease may be Behcet's disease; the prostatitis syndrome may be chronic prostatitis and / or chronic pelvic pain syndrome; (3) The cardiovascular disease is one or more of pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease, stroke or peripheral circulatory disorder; (4) The trauma is one or more of diabetic ulcer, burn, pressure ulcer, acute mucosal injury, including Stevens-Johnson syndrome, mucosal injury, injury related to anticancer chemotherapy, antimetabolites, cellular or humoral immunotherapy or radiation-related injury; for example, the anticancer chemotherapy may be one or more of alkylating agents, DNA synthesis inhibitors or DNA gyrase inhibitors; (5) The autoimmune disease is multiple sclerosis and / or rheumatoid arthritis; (6) The ear disease is one or more of hearing loss, tinnitus, vertigo or imbalance; (7) The eye disease is glaucoma and / or dry eye; (8) The neurogenesis and neuronal cell death are one or more of a psychiatric neurological disease, a neuropathy, a neurotoxic disease, a neuropathic pain, or a neurodegenerative disease; (9) The tissue damage is liver damage and / or muscle damage; the muscle damage is preferably muscle atrophy and / or muscular dystrophy; and (10) The renal disease is chronic renal disease and / or renal failure; Further preferably, the 15-PGDH-related disease is idiopathic pulmonary fibrosis, liver regeneration, liver injury or inflammatory bowel disease.

12. Application of a substance, It is characterized in that The substance is a pharmaceutically acceptable salt of a heterocyclic compound according to any one of claims 1 to 3 or a solvate thereof, a pharmaceutical composition according to claim 9 or a substance X; The substance X is the crystal form A of the compound of formula I-3B according to any one of claims 4 to 7, the crystal form B of the compound of formula I-3B, the crystal form of the hydrochloride of the compound of formula I-3B, the crystal form of the phosphate of the compound of formula I-3B, the crystal form of the fumaric acid complex of the compound of formula I-3B, the crystal form of the L-tartrate of the compound of formula I-3B, the crystal form of the p-toluenesulfonate of the compound of formula I-3B, the crystal form of the L-malate of the compound of formula I-3B, the crystal form A of the edisylate of the compound of formula I-3B, the crystal form B of the edisylate of the compound of formula I-3B, the crystal form C of the edisylate of the compound of formula I-3B, the crystal form of the methanesulfonate of the compound of formula I-3B, the crystal form of the benzenesulfonate of the compound of formula I-3B, or the crystal form of the oxalate of the compound of formula I-3B; The application is to prepare drugs for preventing or treating the following diseases; the diseases are one or more of fibrotic diseases, inflammatory diseases or tissue damage; For example, the fibrotic disease, the inflammatory disease and the tissue damage are all as described in claim 11.

Citation Information

Cited By

  • Preparation of compound containing heterocyclic compound or compound formed by heterocyclic compound and pharmaceutically acceptable salt as well as preparation method and application of preparation

    CN121987634A

  • Use of heterocyclic compound and complex formed by heterocyclic compound and pharmaceutically acceptable acid

    WO2026098592A1

  • Formulation containing heterocyclic compound or complex formed from heterocyclic compound and pharmaceutically acceptable salt, preparation method therefor, and use thereof

    WO2026098600A1